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Abstract 
The flap endonuclease superfamily of 5'-nucleases have roles in DNA replication and repair. 
They react with DNA via a conserved nucleolytic core, co-ordinating with divalent metal ions 
to hydrolyse DNA in a structure-specific manner. Two examples are: flap endonuclease 1 
(FEN1), which acts in Okazaki fragment maturation (OFM) during DNA replication, and 
exonuclease 1 (EXO1), which is important in DNA repair pathways. Although FEN1 has been 
extensively studied in the past, EXO1 has not been thoroughly examined. Therefore, this 
project focused on better understanding EXO1 by exploring commonalities and differences to 
FEN1. 
EXO1 is primarily an exonuclease, removing nucleotides from dsDNA ends. This 
thesis describes biochemical analyses of the exonucleolytic capabilities of human EXO1 
(hEXO1). Establishment of the enzymes substrate specificity, combined with determination 
of the kinetic parameters, allowed for characterisation of features of its reaction mechanism. 
In particular, experiments demonstrated that hEXO1 reactions were rate-limited by product 
release at high substrate concentrations. FEN1 processes endonucleolytic substrates by 
passing 5'-ssDNA flaps through a helical archway, which is conserved in EXO1. EXO1 also 
has suggested involvement in OFM; therefore, investigation of whether hEXO1 threads its 
endonucleolytic substrates was undertaken. Preventing or capturing the threaded state with a 
biotinylated substrate and streptavidin demonstrated that EXO1 must thread flapped substrates 
prior to catalysis. Further studies using multiple FEN1 mutants at residues expected to stabilise 
the threaded state, in combination with substrates with differing 5'-modifications, identified 
R104 and K132 as important residues for interaction with the +1 phosphate. Arch residue 
R129 was also identified as being required for efficient catalysis. 
Biophysical analyses of EXO1 by CD determined that a signal change observed for 
hFEN1 with substrates containing tandem 2-aminopurines was not produced with hEXO1. 
However, the DNA base distortion hypothesised to cause the observed shift in FEN1 crystal 
structures is also present in EXO1 crystals. Finally, multiple N-hydroxyurea inhibitors known 
to inhibit hFEN1 were shown to be non-specific to FEN1 as biochemical and biophysical 
techniques demonstrated interaction with and inhibition of hEXO1.   
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Chapter 1: Introduction 
1.1 DNA and nucleases 
Deoxyribonucleic acid (DNA) has been well established as the genetic material for decades 
[1-2]. Important information is stored as DNA which is transcribed into messenger ribonucleic 
acids (mRNA’s) before being translated into proteins via codon matching with transfer RNA 
(tRNA) at the ribosome [3]. The polymeric structure of DNA is composed of monomeric 
nucleotides; nucleotides consist of a negatively charged monophosphate connected to a 
deoxyribose sugar [4]. Each nucleotide contains one of four nucleobases; adenine, guanine, 
cytosine and thymine, connected to the deoxyribose at carbon-1; three nucleotides code for an 
amino acid. Nucleotides form a polymeric structure which is the basis of DNA; each phosphate 
forms a phosphodiester bond with the hydroxyl group at carbon-3 of the next nucleotides 
deoxyribose. The phosphodiester bond is very stable, but it can be broken by DNA hydrolysis 
(Figure 1.1). Natural decay of this bond is very slow under biological conditions, with a half-
life of approximately 30 million years. However, enzymes known as nucleases catalyse DNA 
phosphodiester hydrolysis on the biologically relevant time scale of milliseconds [5].  
Figure 1.1: DNA hydrolysis. The phosphodiester bond is broken via a pentavalent 
intermediate or transition state with a water molecule acting as the nucelophile. 
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The capability of nucleases to hydrolyse DNA is utilised for various mechanisms in 
the cell. They have roles in DNA replication, repair mechanisms and DNA metabolism. 
Nucleases have two modes of specificity. Sequence-specific nucleases [6], such as restriction 
endonucleases, target a certain sequence within the DNA, are thought to have evolved as a 
defence to bacteriophages and spread by horizontal gene transfer [7]. Structure-specific 
nucleases, as the name would suggest, target a specific structure in the DNA, such as a double 
flap junction [8]. This thesis will focus on structure-specific nucleases.   
1.2 DNA and cell replication 
1.2.1 DNA replication 
DNA replication is a highly regulated process that generates DNA copies precisely and 
efficiently. For example, the human genome consists of roughly 3 billion pairs of either GC 
and AT nucleotide pairs which encode genes, promoters, and various other components. The 
replication of the human genome is achieved by DNA polymerases (Pols), which chemically 
link nucleotides together. DNA elongation is a bidirectional process which is efficient at 
synthesising DNA in a 5' to 3' polarity, producing a long continuous strand known in the case 
of the leading strand. On the other hand, DNA synthesis of the opposing strand is more 
difficult as the strand only becomes accessible as the replication fork is unwound by a DNA 
helicase. Replication is still a 5' to 3' process, but it must be constructed in fragments as the 
DNA becomes accessible. In eukaryotes, primase and Pol α introduce primers which are 
extended by Pol δ and proliferating cell nuclear antigen (PCNA), generating ~50 million non-
continuous strands otherwise known as Okazaki fragments [9-11]. This process is also known 
as lagging strand synthesis.  
The lagging strand constructed from these Okazaki fragments in the process of 
Okazaki fragment maturation [12-13]. Elongation of the RNA primers generates overlapping 
sequences between the fragments which form “flapped” structures that must be removed 
before ligation by DNA ligase. Early work with cell extract isolated maturation factor 1 which 
was identified as being necessary for this process [14]. This factor was later aptly renamed 
flap endonuclease 1 (FEN1), a structure-specific nuclease responsible for the removal of these 
flaps, with a substrate requirement for a single nucleotide 3'-flap [12]. It has been suggested 
that RNase H cleaves the primer to a single ribonucleotide, and then FEN1 displaces the 
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remainder of the primer into a 5'-flap and cuts one nucleotide into the duplex producing a 
nicked duplex which can be ligated forming a continuous sequence [13, 15-16]. 
Figure 1.2: DNA synthesis and Okazaki Fragment Maturation. DNA synthesis has to occur 
in two directions; continuous 5' to 3' leading strand synthesis and discontinuous 5' to 3' 
lagging strand synthesis. A. A topoisomerase unravels the DNA helix and a helicase melts the 
DNA strands to allow for synthesis of both parent strands. B. The strands are elongated 5' to 
3' by DNA polymerase δ from an RNA primer, however lagging strand synthesis can only 
occur in short Okazaki fragments that require combination. C. A flap is displaced by strand 
displacement synthesis which requires flap migration to form the optimal substrate of FEN1. 
D & E. After the removal of the flap by FEN1 one nucleotide into the duplex the major product 
only requires ligation by DNA ligase.  
1.2.2 Genetic recombination 
Cell replication requires equal division of DNA that is replicated during S-phase (as above); 
mitosis allows for the formation of two daughter cells from an initial mother cell, which are 
clones of the original [17]. Meiosis is a process similar to mitosis; the genetic material is also 
split evenly between cells but eventually, after two rounds, provides sex cells with one full set 
of chromosomes (half that of a somatic cell) [18]. Meiosis I separates chromosome pairs that 
are aligned along the spindle fibres before cell division, this produces cells with one set of 
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chromosomes but double the DNA content (2n). Meiosis II is a second division event which 
provides cells with a single set of chromosomes, which can develop into sperm or eggs.  
 
Figure 1.3: DNA Meiosis. A. Meiosis I begins with chromosome pairs with 2n DNA lining up 
along the centre attached to the spindle by the centromere. The spindle fibres retract, 
separating chromosome crossovers which can result in DNA sharing between the pairs or 
dissolution. B. Meiosis II occurs in the same way, but with single chromosomes which have 
2n DNA. This process separates the chromatids to create four granddaughter cells from the 
original progenitor cell. C. Granddaughter cells are produced which have half the genetic 
material of a normal cell, these can later become sex cells. DNA can be shared between 
chromosomes by this process. 
During meiosis I, after alignment of chromosome pairs, each chromosome can have a single 
break introduced into their sequence. This leaves two free ends which allow the chromosomes 
to strand invade each other, leading to a cross over event generating a single Holliday junction 
(HJ) (figure 1.4), which can branch migrate along the DNA [19]. There are two modes of 
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action for repairing this junction which are dependent of the orientation of the crossover. 
Horizontal resolution (dissolution) unwinds the chromatids and allows for correct separation 
of chromosomes, therefore, no recombination of the two strands takes place [20]. 
Alternatively, if the strands are resolved vertically DNA is exchanged between the 
chromosomes [21-22]. This process can be performed by process can be performed by gap 
endonuclease 1 (GEN1). GEN1 acts as a dimer cutting opposing strands 5'-3' one nucleotide 
into the duplex, which is the same approach FEN1 utilises on 5'-flapped substrates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Chromosomal crossovers and recombination. A. A Holliday junction (HJ); each 
colour represents a separate DNA strand (i-iv), with strand polarity highlighted.Bi-ii. The two 
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conformations the chromatids can form. The strand orientation determines where GEN1 cuts 
the junction, and impacts which strands are shared. 1-4 highlights the helices formed, to 
clarify their locations. Ci. A HJ showing the cleavage points for GEN1, which acts as a dimer. 
The arrows highlight the cleavage sites for Cii and Ciii with black and red respectively. The 
DNA duplexes formed, Cii-iii, are repaired by DNA ligase. This process leads to successful 
and efficient resolution of chromatid crossovers. 
Processing HJs by resolution over dissolution is cell cycle dependent. Dissolution 
occurs during G1, S and G2 phase, whereas resolution takes place primarily in mitosis or 
meiosis. It is unclear as to why this is observed, but it may provide greater genetic diversity in 
sex cells [21, 23]. As illustrated above in figure 1.3, granddaughter cells consist of one set of 
chromatids which can have DNA sharing between chromosomes. Whatever the cause, GEN1 
is an efficient endonuclease which processes HJs in a similar manner to the way FEN1 
processes Okazaki fragments. Another method of chromosomal crossovers is due to double 
strand break repair (DSBR) which is mentioned in the next section (section 1.3.2). The final 
phase relies on DNA repair by homologous recombination via strand invasion [24]. In DSBR 
both strands require repair, which leads to the formation of two HJ’s, however, they are both 
treated in the same was as single HJ’s, like above [19]. 
1.3 DNA repair mechanisms 
1.3.1 Mismatch repair 
As outlined in section 1.2.1, eukaryotic DNA replication utilises three major DNA 
polymerases (Pols) in leading and lagging strand synthesis. Pol α lacks proofreading 
capabilities, meaning it cannot remove incorrectly incorporated nucleotides by 3' to 5' 
exonuclease activity and can only process DNA 5' to 3', whereas the other major replicative 
DNA polymerases (Pol ε and δ) contain proofreading functionality [9]. The ability to remove 
replicative errors increases fidelity of Pols by 100-fold from 1 mismatch in 106 to 1 in 108 
basepairs [25]. However, the human genome is approximately 3 billion base pairs (3x109), 
making it prone to mistakes. DNA mismatch repair (MMR) has evolved to remove any 
mistakes that are not removed by the Pols in tandem with DNA replication. Defects in MMR 
can lead to Lynch syndrome, otherwise known as Heredity Nonpolyposis Colorectal Cancer, 
leaving sufferers susceptible to certain cancers [26-27].    
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The eukaryotic MMR pathway allows for the hydrolysis of long tracts of DNA to 
remove any DNA mismatches inserted. Exonuclease 1 (EXO1) was first identified in 
Schizosaccharomyces pombe, and plays a central role in MMR as the primary nuclease, before 
efficient repair by DNA synthesis with Pol δ and DNA ligase. When a mismatch is inserted 
into DNA it is first detected by the MutSα complex, a heterodimer of MSH2 and MSH6 [28-
30], which clamps around the DNA at the mismatched base pair. This is achieved by a loop in 
MSH6 (Phe-X-Glu) which is conserved in eukaryotes and is even present in the bacterial mutS 
protein [31]. MutSα recognises mismatches primarily, but it can also recognise small 
insertion-deletion loops (IDLs). Upon recognition of a mismatch the protein clamps the DNA 
by ATP hydrolysis. When the protein is clamped it is free to slide along the DNA in the 
presence of ATP [32]. Other MutS complexes exist, but 80-90% of MSH2 is present in the 
MutSα complex [33]. The MutSα heterodimer then forms a larger complex with MutLα, which 
is a heterodimer of MLH1 and PMS2, in an ATP-dependent interaction. Like MutS complexes, 
there are multiple MutL heterodimers, but 90% of MLH1 is in the MutLα form [34-35]. The 
MutSα-MutLα complex can slide along the DNA contour and MutLα is thought to 
discriminate between a mismatch and a canonical base pair [36]. Together MutSα-MutLα 
recognise whether a mismatch is present, allowing for stage two of the repair process. 
PCNA is loaded onto the DNA by replication factor C (RFC) which interacts with the 
MutSα-MutLα complex via MSH6 [37-40]. Early studies into mismatch repair suggested that 
a nick could be introduced 3' and 5' of the mismatch and the error would still be removed. 
However, EXO1 can only perform exonuclease activity 5' to 3', therefore, a nick 3' of the 
mismatch would not be effective for EXO1 utilisation [41]. It was later discovered that MutLα 
introduces a nick into the DNA 5' of the mismatched base pair via discrete endonuclease 
activity of its PMS2 domain [42]. This process was shown to be PCNA-dependent by p21 
inhibition; depletion of PCNA by direct binding with p21 showed a 50% reduction of 5'-
directed nicks and abolished 3'-directed nick activity [43-45]. 
When a nick is introduced upstream of the mismatch EXO1 can remove a tract of 
DNA, including the mismatched base. EXO1 acting with MutSα removes ~2000 nucleotides, 
but when replication protein A (RPA) is also present, DNA removal is reduced to ~250 
nucleotides and nucleolytic activity is terminated after the mismatch is removed [41]. After 
the release of EXO1, the DNA can be repaired with a combination of DNA elongation by Pol 
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δ and ligation by DNA ligase (figure 1.5). Though EXO1 is the most integral nuclease for 
MMR, it has been shown that other nucleases can be used as replacements [46]. FEN1 is also 
thought to act as a back-up for EXO1 by strand displacement, treating the mismatched strand 
as a large flap. These processes allow for genome conservation during replication should the 
proofreading ability of Pol δ and ε fail. 
 
Figure 1.5: Eukaryotic DNA Mismatch Repair. A mismatch is introduced into the DNA, 
highlighted by the red nucleotide. A. MutSα first determines if a mismatch is present before 
clamping the DNA. B. Upon recognition by MutSα it interacts with MutLα and slides along 
the DNA. MutLα is also predicted to help in mismatch discrimination. C. PCNA is loaded onto 
the DNA by RFC, allowing for a nick to be introduced by the discrete endonuclease of the 
PMS2 subunit of MutLα. D. MutSα recruits EXO1 to a nick 5’ of the mismatch. E. EXO1, in 
combination with MutSα, resects around 250 nucleotides, removing the mismatch. RPA binds 
to the ssDNA. F. Shortly after the removal of the mismatch, MutSα promotes EXO1 to stop 
resecting DNA. G. RPA can either release from the DNA or activate the DNA damage 
checkpoint via ATR. H. DNA polymerase δ resynthesises the DNA before DNA ligase fixes the 
ssDNA gap generated.  
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1.3.2 Double strand break repair 
Another form of DNA damage considered the most cytotoxic is breaks in the DNA [47]. Single 
strand breaks are relatively easy to rectify; however, formation of double strand breaks (DSBs) 
can be difficult to repair, relying on various pathways. The pathway used to repair a DSB is 
dependent on the phase of the cell cycle; for example, non-homologous end joining (NHEJ) 
takes place primarily in G1 phase. Therefore, DSB repair (DSBR) is a vastly regulated process 
consisting of two major pathways. The first mentioned above, NHEJ, directly ligates the DNA 
ends back together, but can only perform this role on free unmodified (e.g. not oxidised) ends 
[48]. The second method is homologous recombination (HR), which relies on first resecting 
the DNA at the free 5'-ends generating overhangs [24]. These overhangs are then repaired by 
DNA synthesis with DNA polymerase using the sister chromatids as templates for 
homologous recombination before ligation by DNA ligase. This leaves a repaired DNA 
junction as its product. A third pathway exists known as microhomology-mediated end joining 
(MMEJ), which uses aspects of the other two pathways and is active throughout the cell cycle.  
A heterodimer of Ku70 and Ku80 form the Ku complex which can determine pathway 
choice in a cell cycle-dependent manner [49]. If the cell is in G1 phase, Ku will interact with 
the DSB free ends, preventing DNA resection as the 5'-ends are not accessible by the HR 
nucleases (figure 1.6A) [50]. Therefore, Ku directly inhibits HR and promotes NHEJ. 
Conversely, when the cell cycle is in G2 or S phase, resection removes long tracts of DNA. 
The resulting duplex has no free double-stranded ends for Ku to bind, inhibiting NHEJ (figure 
1.6B). Although both pathways are important, focus will be on HR as EXO1 is central to 
extensive resection.   
In mammalian HR, CtIP and MRN (MRE11-Rad50-NBS1), initiate the process by 
binding at the DSB; this is a required step for HR [51-52]. MRN recruits the two nucleases, 
EXO1 and DNA2, which have slightly different mechanisms of resection (figure 1.6B). For 
DNA2 resection, BLM (Bloom syndrome RecQ helicase) interacts with DNA2 and resects in 
an ATP-dependent manner [24]. CtIP recruits RPA which in turn promotes BLM unwinding 
of the DNA enforcing a 5' to 3' polarity [53]; MRN accelerates this process by promoting BLM 
interaction with the DNA ends [24]. The EXO1 resection mechanism starts with BLM 
increasing EXO1’s affinity for the DNA ends before MRN stimulates and enhances EXO1’s 
processivity [24, 54]. Again, RPA also helps stimulate this process via BLM, maintaining 
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exonuclease activity at the 5'-end. Due to its role in both the DNA2 and EXO1 resection 
methods, BLM is considered to be a dominant protein in DNA end resection [24, 54]. 
However, it has also been shown to have an inhibitory function in homologous recombination 
by preventing Rad51 interaction with the ssDNA [55]. Homologous recombination forms two 
HJ’s via strand invasion of sister chromatids, which is repaired as described in section 1.2.2. 
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Figure 1.6: Mammalian Double Strand Break Repair. A double strand break is introduced 
by endogenous (e.g. DNA polymerase mistakes) or exogenous (e.g. ionising radiation) means. 
The cell cycle stage determines the pathway choice. A. For cells in G1-phase the DSB is 
repaired by non-homologous end joining (NHEJ). The Ku heterodimer binds to the DNA ends, 
inhibiting resection and ensuring NHEJ. Bi. If the cell is in G2 or late S-phase the DSB is 
processed by homologous recombination (HR). CtIP and MRN interact with the ends and start 
the process with the help of the BLM helicase. MRN recruits nucleases to the DNA ends. Bii. 
There are two major nucleases that can process the break, DNA2 and EXO1, with the aid of 
BLM and RPA for polarity discrimination. Biii. Once extensive resection has occurred, the 
product duplex has large overhangs coated with RPA. This can trigger two processes: Biv. 
The RPA can be replaced with Rad51 which encourages HR by strand invasion of the sister 
chromatids. C. Alternatively the RPA-coated DNA can activate the DNA damage checkpoint 
by ATR.  
1.3.3 Base excision repair 
Oxidation is another form of DNA damage, which can result in oxidised nucleobases. Reactive 
oxygen species (ROS) generated either endogenously by leakage from the electron transport 
chain or exogenously by environmental oxidative stressors can lead to oxidation [56-57]. ROS 
can generate oxidative DNA base lesions which has the potential to cause mutations, abnormal 
gene transcription or epigenetic instability, if left in disrepair [56]. An example of an oxidised 
base is 8-oxoguanine (8-oxoG) which forms a non-Watson-Crick base pair with adenine as 
well as its canonical cytosine pairing [58-60].   
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Figure 1.7: Guanine is oxidised to 8-oxoguanine by exogenous and endogenous sources 
allowing it to form hydrogen bonds with adenine as well as cytosine. 
Repairing this lesion can be achieved by multiple methods, but it always begins with 
the removal of the oxidised base. This is achieved by glycosylases; in the case of 8-oxoG the 
aptly named 8-oxoguanine DNA glycosylase is utilised to remove the base, generating an 
abasic (AP) site [59]. AP endonuclease 1 (APE1) generates a nick at the AP site allowing for 
one of three processes to occur [61-62]. For a native deoxyribose sugar which has not been 
oxidised the process requires a combination dRP lyase to remove the 5' deoxyribose sugar and 
Pol β to fill the gap [63]. The two strands are then repaired by DNA ligase. This process is 
known as single-nucleotide base excision repair (sn-BER)(figure 1.8). 
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Figure 1.8: The removal of an oxidised base. A DNA base can be oxidised by exogenous or 
endogenous means; in this example 8-oxoguanine is formed. This is removed by 8-oxoG DNA 
glycosylase generating an abasic site which can be excised by APE1. A. In this case the sugar 
is not oxidised and can be repaired by a combination of DNA Pol β and dRP lyase. Pol β fills 
in the gap and the nick is repaired by DNA ligase. B. Oxidised sugars must be repaired by 
alternative mechanisms. i. One method fills the gap with Pol β, removing the sugar by FEN1 
cutting into the duplex, before Pol β fills the gap again. Finally DNA ligase repairs the nick. 
ii. Alternatively, strand displacement synthesis by Pol β/δ/ε forms a 5’ flap, before migrating 
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to form a more suitable substrate of FEN1. After removal of the flap the DNA simply requires 
ligation to form a repaired duplex. This figure is based on figure 1 of [64]. 
The two other forms of repair deal with an oxidised deoxyribose and rely on Pol β 
(though in some cases other polymerases can also be used), FEN1 and DNA ligase. The second 
pathway, illustrated in figure 1.8Bi, has been referred to as the “Hit and Run” method [65]. 
This description relates to the fact that Pol β first fills the gap created by APE1 with a single 
nucleotide. FEN1 then removes the oxidised deoxyribose and the next nucleotide before Pol 
β fills the second gap generated by the nucleotide’s removal. Finally DNA ligase joins the 
nick. The final method of BER, figure 1.8Bii, begins with strand displacement synthesis by 
Pol β, which generates a 5' flap [66]. Before FEN1 can remove this flap the strand migrates to 
generate a single nucleotide 3' flap. After FEN1 has removed the flap the nick only requires 
processing by DNA ligase. This process is known as strand-displacement BER, and fits into 
long-patch BER with the Hit and Run method. For an oxidised sugar the most efficient process 
is strand-displacement mediated long-patch BER due to the fact that Pol β only has to process 
the sequence once, before FEN1 generates a product that requires minimal processing.  
Defects in the BER pathways lead to predisposition to cancer formation [67]. BER has 
also been linked to the expansion of trinucleotide repeats (TNRs), which are associated with 
various neurodegenerative diseases such as Huntington’s chorea [68-69]. In this case if a base 
is oxidised in a TNR region, BER attempts to repair this error. Upon removal of the oxidised 
base and APE1 cleavage at the AP site generated, the TNR can form a branched structure due 
to DNA slippage [64, 70]. Repair continues as normal but leaves a product with the addition 
of more TNR’s as shown in figure 1.9. An in vivo example implicates the MSH2-MSH3 
heterodimer MutSβ, a mismatch repair protein required for removal of longer IDLs, as being 
essential for expansion of CAG repeats by stabilising the hairpin branches for BER to extend 
the region [71-73].  
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Figure 1.9: Trinucleotide repeat expansion by BER. If BER is required in a region of TNR’s; 
expansion can occur. A & B. A guanine that has been oxidised is removed by OGG1 and the 
abasic site is cleaved open by APE1. C. The DNA slips in this region to form a CAG hairpin 
structure. D. Pol β fills in the gap up to the oxidised sugar. E. FEN1 is unable to remove the 
sugar so close to the hairpin, therefore, the DNA realigns to allow access. F. The flaps migrate 
to form the optimal FEN1 substrate. G. FEN1 removes the flapped structure creating a nicked 
product. H. Finally DNA ligase religates the nick, leaving a repaired duplex with a hairpin, 
successfully expanding the TNR’s on one strand. This figure is based on figure 3 [64]. 
Although BER is a very important process that relies on FEN1, there is one instance 
where it can be hijacked by EXO1 [74]. In antibody maturation an enzyme known as 
activation-induced cytidine deaminase (AID) oxidises cytosine bases to uracil. Normally, 
BER takes over, the base is removed and APE1 opens up a nick. Normally Pol β and FEN1 
would remove the sugar and resynthesise any removed nucleotides. However, in these regions 
it is predicted that EXO1 can resect the DNA, and an error-prone polymerase fills the gaps 
generated. This can cause nucleotide substitutions and alter the sequence in these regions to 
provide greater antibody diversity which is paramount to recognising different antigens [75-
76]. This process is illustrated in figure 1.10.   
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Figure 1.10: Somatic hypermutation in antibody maturation. A. Cytosine nucleotides are 
deaminated to uracil with the addition of water and the removal of NH3. B. Deamination by 
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activation-induced cytosine deaminase (AID) as it scans along the DNA. C. BER enzymes act, 
with a glycosylase to remove the base and APE1 to generate a nick. D. EXO1 hijacks the nick 
and resects tracts of DNA removing multiple uracil nucleotides. E-F. An error-prone DNA 
polymerase fills in the gap, which can cause nucleotide substitutions due to uracils on the 
sister strand as well as mistakes caused by a lack of proofreading capability of the polymerase. 
G. BER attempts repair on the sister strand but is again hijacked by EXO1. H. The repaired 
strand has various nucleotide substitutions providing greater antibody diversity.  
1.3.4 Nucleotide excision repair  
Ultraviolet radiation (UV) causes exogenous damage to DNA, such as the dimerization of two 
adjacent thymine nucleobases leading to unpairing with the complementary strand due to 
internal stacking [77-79].  This dimer is recognised by the xeroderma pigmentosum type C 
(XPC), a member of a pathway of proteins, which initiates repair [80]. The other XP-factors 
coordinate the removal and repair of the bubble. XPA acts as a scaffold for other proteins [81], 
RPA coats the single-stranded DNA,  and TFIIH, a transcription factor for other XP proteins, 
forms a complex with various proteins, including XPD and XPB, which act as bidirectional 
helicases [82]. The nucleases XPF and XPG perform bilateral cleavage of the bubble, starting 
with XPF generating a flapped structure which is removed by XPG [83-84]. Once the DNA 
bubble is removed, DNA polymerase and ligase repair the gap.  
Alternatively, upon removal of the bubble, EXO1 can resect and extend the gap 
generated by the bubble’s removal [85]. The gapped DNA becomes saturated with RPA which 
in turn triggers the ATR pathway [85-86]. ATR refers to a group of ataxia telangiectasia and 
Rad3 related serine/threonine kinases, that in combination with other protein partners and 
various phosphorylation events, trigger the DNA damage response, which leads to apoptosis 
[87].  
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Figure 1.11: Nucleotide excision repair and DNA damage checkpoint activation. Ai. UV 
light generates a thymine dimer, which is recognised by XPC. Aii. The other NER pathway 
proteins coordinate the removal of the DNA bubble. Aiii. The ssDNA gap is repaired by DNA 
synthesis and ligation. Bi. Alternatively, the gapped region is extended by EXO1. Bii. RPA 
coats the ssDNA and initiates the ATR pathway which leads to the activation of the DNA 
damage checkpoint. 
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1.4 The flap endonuclease superfamily  
It is clear that nucleases are important enzymes in pathways relating to genome repair and 
stability. The focus of the repair pathways mentioned has been a conserved family of 
nucleases.  
1.4.1 Family members 
The Flap endonuclease (FEN) superfamily of structure-specific 5' nucleases is a conserved 
family of enzymes which can be traced back to viruses [88]. There are four major DNA 
nuclease members and two ribonuclease members which take part in various DNA/RNA 
replication, repair or metabolic mechanisms. Flap endonuclease 1 (FEN1) is involved in 
Okazaki fragment maturation (section 1.2.1), where the enzyme removes flapped structures 
from patches of DNA in lagging strand synthesis (figure 1.12A-B) [16]. Exonuclease 1 
(EXO1) is a key nuclease in various repair pathways, such as mismatch repair (section 1.3.1) 
and double strand break repair (section 1.3.2), where it removes tracts of DNA errors or 
damage allowing for repair by a DNA polymerase (figure 1.12C-D) [89-90]. Gap 
endonuclease 1 (GEN1) resolves Holliday junctions that form between homologous 
chromosomes (figure 1.12E-F) in meiosis (section 1.2.2) [21, 91]. Xeroderma pigmentosum 
(XPG) is part of a protein pathway charged with removing DNA bubbles generated by 
ultraviolet light damage (section 1.3.4). XPG removes the DNA bubble bilaterally with XPF 
before the duplex is repaired by a DNA polymerase (figure 1.12G-H) [86, 92]. The two RNA 
members are exoribonuclease (XRN) 1 and 2. XRN1 is known to degrade mRNA sequences, 
and XRN2 is thought to be involved in transcription termination; these RNA targeting 
enzymes will not be discussed in detail [93-94].  
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Figure 1.12: The FEN superfamily and their substrates. Cartoon representations highlight 
the key helices in each protein, for example the α2-3 wedge domain and the α4-5 which form 
a helical archway in FEN1 and EXO1. A. Flap endonuclease 1 (FEN1) with a double flapped 
substrate. B. The preferred substrate of FEN1 with a 5' flap of any length and a 3' single 
nucleotide flap. FEN1 cuts one nucleotide into the duplex 5' to 3' and the gap is filled by the 
3' flap. C. Exonuclease 1 (EXO1) with a nicked duplex. D. A nicked substrate is processed 5' 
to 3' removing single nucleotides; interestingly, the major product is also a substrate. E. Gap 
endonuclease 1 (GEN1) as a dimer with a Holliday junction (HJ). F. GEN1 acts as a dimer 
on HJ’s cutting one nucleotide into the junction on both sides; this forms two duplexes that 
can be repaired by ligation. G. Xeroderma pigmentosum type G (XPG) with a DNA bubble 
substrate. H. XPG works in tandem with other repair proteins to process a DNA bubble, XPF 
cuts the opposing side of the bubble before XPG removes the flapped structure generated.  
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Figure 1.13: Sequence alignment of Flap endonuclease superfamily members. The 
sequences were aligned using PROMALS3D with the secondary structure aligned above based 
on the crystal structures of hFEN1 (3Q8K.pdb), hEXO1 (3QEB.pdb) and hGEN1 (5T9J.pdb) 
[16, 89, 91, 95-96]; no crystal structure of hXPG has been assigned at this time. The residue 
consensus is displayed below the protein sequence based on the key at the bottom and 
catalytically important residues are highlighted in boxes. Key structural elements are also 
shown below the protein sequences. Residues 117-763 of hXPG were removed to facilitate the 
fit, and residues 253-305 of hGEN1 were removed from the figure as this loop is only present 
in GEN1. The arrow at the beginning of the sequence shows that the methionine residue in 
position 1 is removed post-translationally.  
All family members have a conserved catalytic core region, which is generally 
confined to the N-terminus of the protein. The exception is XPG which has a large region in 
between the two parts that make up the catalytic domain that is excluded from the alignment. 
The structurally conserved catalytic core is responsible for the nuclease activity of the 
individual proteins, and suggests a unified mechanism. The remainder of the proteins is made 
up of differing C-terminal domains (or in XPG, the gap between the nuclease domains and the 
remainder of the C-terminus) which allow for protein partner interactions that act as controls 
in their respective repair pathways [88]. Greater examination of specific regions of the 
superfamily proteins will encompass the remainder of this chapter. 
1.4.2 The hydrophobic wedge 
A region termed the “hydrophobic wedge” motif is formed by a combination of α2-3 which 
stabilises DNA bending to ~100⁰ in hFEN1 and hEXO1 complexes [16, 89]. This hydrophobic 
wedge is conserved throughout the family members, with a high density of hydrophobic 
residues, especially in α3.  EXO1 also contains an extra helical motif at the top of α2 termed 
α2', which potentially forms interactions with α5 and stabilises reaction once a substrate is 
bound [89]. For example, a possible salt bridge exists between glutamate 44 (E44) and arginine 
116 (R116).  
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Figure 1.14: Crystal structures highlighting key regions. The crystal structures of A. FEN1 
(3Q8K.pdb), B. EXO1 (3QEB.pdb) and C. GEN1 (5T9J.pdb) highlighting the hydrophobic 
wedge (blue), helical gateway (red) and H2TH (yellow) of each protein. Structural gaps in 
GEN1 are displayed by Ci and Cii. 
1.4.3 Helical gateway and cap 
A helical gateway is formed by the lower parts of α2 and α4 as highlighted in the sequence 
alignment. This region forms the radius around the active site above the two divalent cations 
which are required for catalysis [88]. The residues that form the gateway are conserved 
through the superfamily, which is illustrated by figure 1.12 (A, C, E & G). However, the 
gateway is missing from the crystal structure of hGEN1, and as a result is not shown within 
figure 1.13, but the amino acid sequence is relatively conserved.  
The latter portion of α4 combined with α5 acts as a cap at the top of the arch, forming 
a hole in the protein. This archway formation was a subject of controversy for many years 
with respect to how a flapped substrate is processed in hFEN1. However, it has been shown 
recently in both FEN1 and EXO1 that the gateway is big enough to facilitate threading of 
discontinuous flapped substrates through the hole before catalysis [97-101]. Interestingly, this 
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cap is not present in GEN1 and XPG, displayed by a gap in the sequence. This is probably 
related to their characteristic substrate specificities, which involve continuous DNA structures. 
A Holliday junction is a closed duplex and can therefore not be threaded [21]. Whereas, XPG 
removes DNA damage bubbles, hydrolysing the DNA in tandem with another nuclease, which 
could facilitate threading a flapped structure. However, it has been shown that XPG binds to 
the DNA bubble prior to substrate cleavage, and as a result it seems unlikely to thread its 
substrates.   
1.4.4 DNA sliding 
A helix two turn helix (H2TH) motif present at α10-11 in FEN1 and EXO1 or α7-8 in GEN1 
has been shown to co-ordinate with a potassium ion, allowing for interaction with the DNA 
backbone. Crystal structures of superfamily members have not shown the presence of a 
potassium ion in the absence of DNA, suggesting that it co-ordinates when the DNA binds 
[16, 89]. Carbonyl groups act as potassium-binding sites with water molecules; also, in FEN1 
and EXO1 the hydroxyls of serine 237 and 229 respectively have been implicated. The 
K+/H2TH motif may facilitate local sliding of the protein on DNA, allowing junction seating 
to occur; this has been likened to the sliding capability of DNA polymerase β [102]. 
1.4.5 Less significant helical motifs 
Other structural elements act in stabilising the enzymes. After the helical gateway, α6 (part of 
α4 in GEN1) spans the back of the hydrophobic wedge with various hydrophobic residues 
facing internally in the protein allowing for protein stability, whilst externally facing residues 
are either charged or polar. The α7 helix (α5 in GEN1) forms a scaffold through the centre of 
the enzyme, with cation-stabilising residues at the top of the helix. In FEN1 and EXO1 α8 has 
a similar role in cation stability. Various carboxylic residues are present around the active site 
for co-ordination of the metal ions, which will be mentioned below. 
1.4.6 Active site residues 
The active site co-ordinates divalent cations involved in catalysis of the reaction with various 
conserved acidic residues. These have been highlighted by blue boxes in figure 1.13, and 
include D34, D86, E159, E160, D179, D181 and D233 (FEN1 numbering) [16]. These 
residues are conserved through all the family members and emphasise the importance of the 
divalent metal ions in catalysis (figure 1.15A) [103]. Another key feature is the mainchain 
amino of G2 (as M1 is removed post-translationally), which is conserved in all the enzymes, 
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and is suggested to interact with the nucleophilic water molecule that is added to the phosphate 
to hydrolyse the phosphodiester bond in FEN1 and EXO1 (figure 1.15B) [99]. 
Basic residues on the gateway interact with the oxygen atoms of the phosphodiester 
backbone, helping to stabilise the polynucleotide in the active site. For example, R104 is 
required for interaction with the 5’-phosphate (data collected as part of this thesis) in hFEN1. 
Also R100 mutants are catalytically inactive relative to wild-type (10,000-fold down). All 
basic residues highlighted in red are important for FEN1 catalysis, and are conserved through 
the superfamily (figure 1.15B) [99-100]. 
One last feature present in only FEN1 and EXO1 is a stacking residue present in α2, 
shown in figure 1.15B. The residue (Y40 in FEN1; H36 in EXO1) stacks with the nucleobase, 
allowing for a smooth transition of the nucleotide into the active site [16, 89, 99-100]. This 
interaction could be important in threading of substrates or at the very least positioning of the 
scissile phosphate, and significant drops in activity have been observed upon mutagenesis. No 
obvious stacking residue is present in GEN1 and XPG, which could represent its importance 
in discontinuous DNA substrates. 
Figure 1.15: The active site residues of hFEN1. The crystal structure of hFEN1 (3Q8K.pdb) 
was used to display the key residues that are conserved in the superfamily for catalysis. A. 
The carboxylate residues that interact with the divalent cations, forming a halo around the 
active site. B. The active site residues with distances in angstroms; R100 and K93 interact 
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with the phosphate in combination with the divalent metal ions. The aromatic residue, Y40, 
which is only conserved in FEN1 and EXO1 shows stacking interactions with the nucleobase. 
The G2 amino is positioned into the active site for interaction with the water molecule.  
1.4.7 Enzyme specific regions 
As discussed throughout sections 1.2 and 1.3, each family member takes part in different repair 
pathways, although in some cases they can act as back-ups for one another. FEN1 has a 
requirement for single nucleotide 3' flaps, allowing for quick repair by DNA ligase when 
FEN1 cuts one nucleotide into the 5' duplex as the 3' fills the gap. To do this hFEN1 has 
developed a specialised pocket to facilitate 3' flap binding, aptly named the 3' flap binding 
pocket. This binding domain is made up of α14-15 helices and the looped region between α2 
and 3. As shown in figure 1.16A-B, the crystal structure demonstrates a clear accommodation 
of the flap into the pocket [16]. The amino acid sequence beyond α15 forms a loop that 
contains a PIP-box for PCNA binding [103-104]. 
In the case of hEXO1, which takes part in multiple repair pathways, the enzyme 
contains an extended C-terminal domain for binding its protein partners from different 
pathways. Helices α14-15 of EXO1 form along the back of the enzyme, and begin the extended 
C-terminal region, shown in the crystal structure [89]. In figure 1.17 the N-terminal core 
represents the 352 amino acids present in the crystal structure (3QEB.pdb) and displays 
protein-partner binding sites in the extended C-terminus beyond. The binding domains are for 
MSH3, MLH1 and MSH2, which are components of MutSβ, MutLα and MutSα respectively 
[105]. These proteins are all important in mismatch repair and represent a small number of 
binding partners. EXO1 is also postulated to have a PIP-box [104]. 
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Figure 1.16: The C-terminal regions of family members. The crystal structures of hFEN1 
(3Q8K.pdb), hEXO1 (3QEB.pdb) and hGEN1 (5T9J.pdb) with C-terminal regions in purple. 
The red, yellow and blue motifs represent the helical archway (in FEN1 and EXO1), H2TH 
motif and hydrophobic wedge respectively. A. hFEN1 with a double flap DNA substrate. B. 
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The 3' flap binding pocket of hFEN1 (α14-15 and regions of the α2-3 loop) highlighted in 
purple; this region accommodates a single nucleotide 3' flap. C. The front of hEXO1 
displaying the nucleolytic core D. The back of hEXO1 shows the extended C-terminus that has 
been crystallised, prior to the enzymes truncation at 352 amino acids. E. The structure of 
hGEN1 with the chromodomain highlighted in purple. F. The hGEN1 crystal structure 
modelled with the DNA used to crystallise C. thermophilum GEN1 (5CO8.pdb) illustrating 
how DNA could interact with that region.  
The GEN1 substrate, the Holliday junction, is a 4-way junction made of continuous 
DNA strands that forms from crossover events of sister chromatids [21]. GEN1 acts as a dimer 
and must interact on opposing junctions of the 4-way junctions. As a result the extended C-
terminal region contains a chromodomain which allows for extra DNA interaction to stabilise 
this process (figure 1.16E-F) [91]. In the case of hXPG, not a lot is known about the regions 
outside of the nucleolytic core, which are expected to be unstructured. Some evidence of a 
TFIIH binding site has been reported; TFIIH is a transcription factor used in the NER pathway 
[106].  
 
Figure 1.17: EXO1’s Protein Partners in Mismatch Repair. The binding domains for MSH3, 
MLH1 and MSH2 which are members of heterodimers with other proteins to form important 
mismatch repair complexes. The magenta region at the end is to illustrate an overlap of the 
MSH2 and the second MLH1 binding domains.  
1.5 Project aims 
Human flap endonuclease 1 (hFEN1) has been extensively studied over the last decade. 
However, the other members of this family have not been examined in great detail. As the 
member of the family with the most sequence and structural homology to hFEN1 is hEXO1, 
this was the focus of this project. By studying the enzyme’s substrate specificity, kinetic 
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parameters of its exonuclease and endonuclease capabilities and various elements of substrate 
dynamics it is hoped that a reaction mechanism can be determined. This may provide clues to 
whether there is a universal reaction mechanism for the whole superfamily, despite their 
diverse roles in vivo. Testing of hEXO1 with compounds known to inhibit FEN1 will be 
performed to determine their specificity for FEN1. Finally, further studies into the threading 
capabilities of hEXO1 and determination of residues important for phosphate steering in 
hFEN1 and hEXO1 will be performed in the hopes of providing therapeutic targets for the 
future. 
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Chapter 2: Materials and Methods 
2.1 Tables of buffers 
2.1.1 Media and buffers for expression and purification 
Buffer Ingredients  
Luria Bertani Broth (LB) 
1L 
10 g tryptone, 10 g NaCl , 5 g yeast extract 
Terrific Broth (TB) 1L 12 g tryptone, 24 g yeast extract 
SOB media 1L 20g tryptone, 0.5 g NaCl, 5 g yeast extract, 10 mL 250 mM 
KCl, 10 mL 1 M MgCl2  
SOC media SOB media supplemented with 20 mM D-glucose 
Inoue buffer 10 mM PIPES, pH 6.7, 55 mM MnCl2, 15 mM CaCl2 and 250 
mM KCl 
50×5052 (0.5%, 0.05% 
and 0.2% final - 5052) 
25% glycerol, 2.5% glucose, 10% allolactose 
20×Phosphate 1 M Na2HPO4, 1 M KH2PO4, 0.5 M (NH4)2SO4 
1000× metals 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 
mM CoCl2, 2 mM CuCl2, and 2 mM NiCl2 
Autoinduction media 
(AIM) 5 mL 
4.64 mL LB, 10 μL 1 M MgSO4, 1 μL 1000× metals, 100 μL 
50×5052, 250 μL 20×Phosphate – Supplemented with 
antibiotics as appropriate 
AIM 0.5 L 464 mL TB, 1 mL 1 M MgSO4, 0.1 mL 1000× metals, 10 mL 
50×5052, 25 mL 20×Phosphate - Supplemented with 
antibiotics as appropriate 
10×Phosphate Buffer 
Saline (PBS) 
1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM 
KH2PO4, pH 7.4 
IMAC A1 20 mM tris, pH 7.0, 1 M NaCl, 5 mM imidazole, 0.02% (w/v) 
NaN3, (5% glycerol (v/v)*) 
IMAC A2 20 mM tris, pH 7.0, 0.5 M NaCl, 40 mM imidazole, 0.02% 
NaN3, 0.1% Tween-20 (v/v), (5% glycerol (v/v)*) 
IMAC B1 250 mM imidazole, pH 7.2, 0.5 M NaCl, 0.02% (w/v) NaN3, 
(5% glycerol (v/v)*) 
Anion A1 20 mM tris, pH 8.0, 1 mM EDTA, 0.02% (w/v) NaN3, 20 mM 
β-mercaptoethanol (βME) 
Anion B1 20 mM tris, pH 8.0, 1 mM EDTA, 1 M NaCl, 0.02% (w/v) 
NaN3, 20 mM βME 
Dialysis  Buffer 25 mM tris, pH 8.0, 150 mM NaCl, 14 mM βME 
Cation A1 100 mM tris, pH 7.0, 100 mM NaCl, 1 mM EDTA, 5% glycerol 
(v/v), 5 mM dithiothreitol (DTT) 
Cation B1 100 mM tris, pH 7.0, 500 mM NaCl, 1 mM EDTA, 5% glycerol 
(v/v), 5 mM DTT 
2× Storage Buffer 100 mM HEPES, pH 7.5, 200 mM KCl, 2 mM CaCl2, 0.04% 
(w/v) NaN3, 10 mM DTT, (20% glycerol (v/v)*) 
Storage Buffer 50 mM HEPES, pH 7.5, 100 mM KCl, 1 mM CaCl2, 0.02% 
(w/v) NaN3, 50 mM DTT, 50% glycerol (v/v) 
*glycerol supplemented in optimised purification scheme 
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2.1.2 Reaction Buffers 
Buffer Ingredients 
1× Resolving Buffer 375 mM Tris, pH 8.8, 0.1% (w/v) SDS 
1× Stacking Buffer 125 mM Tris, pH 6.8, 0.1% (w/v) SDS 
10× Reaction Buffer 
(RB) 
0.5 M HEPES, pH 7.5, 1 M KCl, 80 mM MgCl2, 1 mg/mL 
bovine serum albumin (BSA) 
1× Reduced RB (RRB) 50 mM HEPES, pH 7.5, 100 mM KCl, 8 mM MgCl2, 0.1 mg/mL 
BSA, 1 mM DTT 
10× Folding Buffer (FB) 0.5 M HEPES, pH 7.5, 1 M KCl 
1× FB 50 mM HEPES, pH 7.5, 100 mM KCl 
Quenchflow (QF) Purge 
Buffer 
50 mM HEPES, pH 7.5, 100 mM KCl, 8 mM MgCl2, 0.1 
mg/mL, 0.02% NaN3 
QF single turnover (ST) 
push buffer 
55 mM HEPES, pH 7.5, 110 mM KCl, 8 mM MgCl2, 0.02% 
NaN3, 15% glycerol 
QF ST quench 1.5 M NaOH, 50 mM EDTA 
5×Tris Borate EDTA 
(5×TBE) 
54g Tris base, 27.5g boric acid, 20 mL 0.5 M EDTA, pH 8.0 
Dilute down to 1×TBE 
Denaturing PAGE gel 
0.25L 
105.1g urea, 100 mL 5×TBE, 50 mL 19:1 acrylamide. Mix with 
gentle heat until dissolved; make up to 250 mL with deionised 
water 
Denaturing PAGE 
loading buffer 
80% formamide, 10 mM EDTA, 1 mg/mL bromophenol blue 
and/or 1 mg/mL xylene cyanol FF. Can be run without dye.  
Circular Dichroism (CD) 
RB 
50 mM HEPES, pH 7.5, 100 mM KCl, 10 mM CaCl2, 1 mM 
DTT 
Förster Resonance 
Energy Transfer (FRET) 
RB 
50 mM HEPES, pH 7.5, 100 mM KCl, 10 mM CaCl2, , 0.1 
mg/mL BSA, 1 mM DTT 
Calcium SA* RB 25 mM HEPES, pH 7.5, 50 mM KCl. 2 mM CaCl2, 0.1 mg/mL 
BSA, 0.5% glycerol, 1 mM DTT 
Magnesium SA* RB 25 mM HEPES, pH 7.5, 50 mM KCl. 16 mM MgCl2, 0.1 mg/mL 
BSA, 0.5% glycerol, 1 mM DTT 
EDTA SA* RB 25 mM HEPES, pH 7.5, 50 mM KCl. 2 mM EDTA, 0.1 mg/mL 
BSA, 0.5% glycerol, 1 mM DTT 
Calcium SA* push 
buffer 
25 mM HEPES, pH 7.5, 50 mM KCl, 2 mM CaCl2, 0.1 mg/mL 
BSA, 0.02% NaN3, 15% glycerol 
Magnesium SA* push 
buffer 
25 mM HEPES, pH 7.5, 50 mM KCl, 16 mM MgCl2, 0.1 mg/mL 
BSA, 0.02% NaN3, 15% glycerol 
SA* Quench 8 M Urea, 300 mM EDTA 
*SA = Streptavidin 
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2.2 Purification of hEXO1-352 
2.2.1 Generation of competent cells by the Inoue method 
Chemically competent cells were produced via the Inoue methodology [107]. Previously 
produced BL21(DE3)-RIPL (CmR) competent E coli cells were plated onto 1.5% agar LB 
plate supplemented with 34 μg/mL chloramphenicol (Cm) and grown for 16-20 hours at 37 
⁰C. A single colony was used to inoculate 25 mL of LB broth containing 34 μg/mL Cm and 
incubated for 6-8 hours at 250 rpm. Three 1L flasks containing 250 mL of SOB media 
containing 34 μg/mL Cm were inoculated with 6, 4 and 2 mL before incubation overnight at 
18-22 ⁰C at 200 rpm. The following morning the OD600 of the cultures was monitored, 
checking every 45 minutes. Once one of the cultures reached an OD600 of 0.55 the flask was 
placed in ice-cold water for 10 minutes and the other cultures were discarded appropriately. 
The chosen cells were centrifuged for 10 minutes at 2500 xg at 4 ⁰C before the removal of the 
supernatant and the pellet was thoroughly dried. The pellet was resuspended in 80 mL of ice-
cold Inoue buffer by swirling. The cells were once again centrifuged for 10 minutes at 2500 
xg at 4 ⁰C and the pellet was thoroughly dried. The pellet was then resuspended in 20 mL of 
ice-cold Inoue buffer before the addition of 1.5 mL of DMSO and mixing by swirling. The 
mixture was stored on ice for 10 minutes, and then 100 μL aliquots were dispensed into 1.5 
mL eppendorfs and flash frozen with liquid nitrogen. The cells were stored at -80 ⁰C before 
until required for transformation.  
2.2.2 Cloning and expression of hEXO1-352 
A codon-optimised (for E coli) truncated human EXO1 plasmid was acquired from GeneArt 
(Thermo Fisher scientific) with a TEV-cleavable-(His)6 tag coded into the sequence (available 
in figure A1 in the appendix). The optimised construct was subcloned into the pET21a vector 
(Novagen) (AmpR) using the NdeI and NotI restriction sites. This expression vector (graphic 
representation is available in figure A2 in the appendix) was transformed into chemically 
competent BL21(DE3)-RIPL (CmR) E coli cells (cells were produced by the Inoue method in 
section 2.2.1). Approximately 50 ng of vector was incubated with 50 μL of cells for 30 minutes 
on ice, before heat shocking at 42⁰C for 90 seconds. The cells were then returned to the ice 
for 5 minutes before being rescued by the addition of 1 mL of SOC media and incubation at 
37⁰C for one hour. The cells were plated on LB-Agar plates supplemented with 100 μg/mL 
ampicillin (Amp) and 34 μg/mL Cm.  
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The hEXO1-352-TEV-(His)6 protein (the exact protein sequence is available in figure 
A3 in the appendix) was produced first by the inoculation of a 25 mL LB starter culture 
supplemented with 100 μg/mL Amp and 34 μg/mL Cm and allowed to grow for 16-17 hours 
overnight at 37⁰C. Autoinduction media [108] was used to induce the plasmid in multiple 2L 
flasks, each containing 500 mL of media supplemented again with 100 μg/mL Amp and 34 
μg/mL Cm, with inoculation with 5 mL of starter culture and grown for 4 hours at 37⁰C with 
shaking at 210 rpm. After this fast-growth period of incubation the temperature was reduced 
to 21⁰C and the culture was grown for between 14-16 hours to an OD600nm of 14-18. The 
cultures were pelleted by centrifugation at 6000 ×g for 20 minutes at 4⁰C, and washed with 
ice-cold 1×PBS after the removal of the supernatant before further centrifugation at 4000 ×g 
for 15 minutes at 4⁰C. The supernatant was discarded once again and the pellet was 
resuspended in lysis buffer (IMAC A1) plus a final concentration of 5 mM β-mercaptoethanol 
and incubated at 4⁰C on a roller mixer for 1-2 hours. Lysis was completed by freezing at -
20⁰C and the lysate was stored until use.  
2.2.3 Purification of hEXO1-352 
Cell lysates were sonicated using a Vibra-cell VCX-130 ultrasonic liquid processor (Sonics & 
Materials, inc) at 70% amplitude for 10 seconds on and 20 seconds off until smooth, before 
the supplementation of 10% Tween-20 to a final w/v of 1%. The resulting solution was 
centrifuged at 30,000 xg for 20 minutes at 4⁰C to separate the soluble and insoluble fractions. 
All purification columns were supplied from GE healthcare and columns were used in 
conjunction with an Äkta pure FPLC (GE healthcare). Initial purification success of hEXO1-
352-TEV-(His)6 was achieved by the following methodology. The supernatant was loaded 
onto three tandem 5 mL crude Co2+-affinity chromatography column (immobilised metal-
affinity chromatography (IMAC)) and elution was achieved with a 10 column volume (CV) 
gradient of 40-250 mM imidazole (IMAC A2 and B1 with 5 mM β-mercaptoethanol). The 
fractions containing hEXO1-352-TEV-(His)6 were loaded onto a 5 mL HiTrap Q anion 
exchange column to remove DNA contamination; due to the fact that hEXO1-352 binds to 
DNA it flows through the positively charged column.  
The 6-His tag was removed by TurboTEV in the ratio described in the manufacturer’s 
instructions (Bioscience, Ltd), 1 unit TurboTEV to 10 μg of target protein; concentrations 
were approximately determined via the Bradford assay. To do this 50 μL of sample was added 
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to 950 μL of Bradford reagent (Bio-rad; named bio-rad reagent), incubated for 5 minutes at 
room temperature and absorbance was determined at 595 nm using a Nanodrop microvolume 
spectrophotometer (ThermoFisher scientific). The protein was dialysed into an appropriate 
buffer for TurboTEV with low enough NaCl (the buffer was changed once, and dialysis was 
in 2L’s of buffer) for successful loading onto the next column. The dialysed sample was 
centrifuged at 4,000 rpm for 20 minutes at 4⁰C to remove any precipitate and loaded onto a 5 
mL HiTrap SP-Cation exchange column pre-equilibrated with Cation buffers A1 and B1, with 
elution by a 10-column volume gradient of 100-500 mM NaCl. The cation exchange flow-
through was re-run through the cation exchange column again several times to extract as much 
hEXO1-352 as possible from the dialysed solution. Finally the pure protein was concentrated 
to a volume of 10 mL and desalted into 2× storage buffer by desalting with a 50 mL HiPrep 
26/10 desalting column. The desalted sample was concentrated by Vivaspin-20 centrifugal 
concentrators to 200 μM of enzyme (determined by absorbance at 280 nm using a Nanodrop 
microvolume spectrophotometer, the molecular weight and extinction coefficient shown 
below) before dilution 1:1 with 100% glycerol that had been treated with Chelex-100 and 
stored at -20⁰C. This mechanism produced ~10 mL of pure 100 μM hEXO1-352 from 8 litres 
of cell culture. Human EXO1-352 has a molecular weight of 40427.9 Da and an extinction 
coefficient of 28475 M-1 cm-1 (at 280 nm, assuming all cysteines are reduced, which was 
determined using ExPASy ProtParam tool (https://web.expasy.org/protparam/)) 
2.2.4 Optimised purification of hEXO1-352 
Protein purification was optimised to develop a more efficient scheme. The addition of 5% 
glycerol stabilised hEXO1-352 against precipitation. The cells were grown, lysed, sonicated 
and centrifuged above to separate the soluble and insoluble fractions. The supernatant was 
diluted with gentle mixing 1:1 with deionised water before loading onto a three tandem 5 mL 
crude Co2+-affinity chromatography column. The standard IMAC buffers were supplemented 
with 5% glycerol and 2.5 mM β-mercaptoethanol. A column wash was performed with 40 mM 
imidazole (IMAC A2) before isocratic elution with 250 mM imidazole (IMAC B1). Fractions 
containing hEXO1-352-TEV-(His)6 were loaded onto a 5 mL HiTrap SP-Cation exchange 
column. This step combined the removal of DNA contamination with isolation of positively 
charged enzymes. The protein was eluted using a gradient between 100-500 mM NaCl with 
Cation buffers A1 and B1. The eluted sample was incubated with TurboTEV as described 
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above overnight at 4⁰C to remove the 6-His tag. TurboTEV was removed from solution by 
incubation at 4⁰C for 1 hour on a roller mixer with MagneGST beads (Promega corporation) 
per the manufacturer’s instructions. Finally the pure protein was concentrated in batches of 10 
mL and desalted into 2× storage buffer containing 20% glycerol using a 50 mL HiPrep 26/10 
desalting column. Samples were concentrated to 200 μM of protein (determined at 280 nm 
using a nanodrop microvolume spectrophotometer), and diluted with 80% glycerol to a final 
w/v of 50%, and stored at -20⁰C. This optimised scheme produced ~30 mL of pure 100 μM 
hEXO1-352 from 4 litres of cell culture.  
Protein purity was determined by analysis of various concentrations by a 12% 
Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-PAGE); composed of 
an 8 cm resolving gel (1× Resolving buffer) and a 2 cm stacking gel (1× Stacking buffer). 
Gel layers contained 12% acrylamide and were polymerised with 0.1% APS and TEMED. 
Separation was performed at 250 volts for 30 minutes followed by staining with InstantBlue 
protein stain (Sigma-Aldrich) for 20 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: SDS-PAGE purity gel of hEXO1-352 after purification. Lane 1: Protein Ladder 
(Precision plus proteinTM all blue stained protein standard; Bio-rad – weights to the left of 
gel), lanes 2-6 contain 1, 2, 4, 8 and 16 μg of protein respectively. Enzyme mass load was 
determined based on 100 μM sample equating to ~4 μg/μL.  
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2.3 Oligonucleotide sequences and constructs used herein 
2.3.1 Oligonucleotide strand sequences 
The oligonucleotides (Table 2.1) were produced and HPLC-purified by LGC Biosearch. All 
the sequences used are detailed below with modifications included; a combination of the 
oligonucleotides used in various constructs are shown in their respective section. 
Table 2.1A: Kinetic oligonucleotide sequences used herein 
Oligo Sequence 
E1 5'-FAM-ACAAGGACTGCTCGACAC-3' 
E2 5'-PHOS-ACAAGGACTGCTCGACAC-FAM-3' 
E3 5'-ACAAGGACTGCTCGACAC-FAM-3' 
E4 5'-PHOS-ACAAGGACTGCTCGACAC-3' 
F1 5'-FAM-TTTTTACAAGGACTGCTCGACAC-3' 
F2 5'-TTTTTACAAGGACTGCTCGACAC-FAM-3' 
F3 5'-FAM-TTTTTTTTTTGAGGCAGAGTAGGACC-3' 
T1 5'-GTGTCGAGCAGTCCTTGTGACGACGAAGTCGTCC-3' 
T2a 5'-BioTEG-GGTCCTACTCTGCCTCAAGAGAGAGACGGTCTGCTGCACTGGATCTGG-3' 
T2b 5'-BioTEG-CCAGATCCAGTGCAGCAGACCGTCTCTCTCC-3' 
T3 5'-GTGTCGAGCAGTCCTTGT-3' 
T4 5'-GTGTCGAGCAGTCCTTGTGACGACGAAGTCGTC-3' 
T5 5'-GTGTCGAGCAGTCCTTGTGACGAC-3' 
Bio-psY 5'-FAM-BioTEG-GAACACACAGAACACACACCGCTTGCGGTGTGTGTTTCCACAAC-3' 
Table 2.1B: ECCD oligonucleotide sequences used herein 
Oligo Sequence 
EEC1 5’-PHOS-2-AP-2-AP-GAGGCAGAGTG-3’ 
EEC2 5’-PHOS-G-2-AP-2-AP-AGGCAGAGTG-3’ 
FEC1 5’-TTTTT-2-AP-2-AP-GAGGCAGAGTG-3’ 
FEC2 5’-TTTTTG-2-AP-2-AP-AGGCAGAGTG-3’ 
UEEC1 5'-PHOS-2-AP-2-AP-GAGGCAGAGTGCGTGCACTCTGCCTCTTGACAGCG-3' 
UEEC2 5'-PHOS-G-2-AP-2-AP-AGGCAGAGTG CGTG CACTCTGCCTTTCGACAGCG-3' 
TC1 5’-CACTCTGCCTCTTGACAGCGAAGCTGTCC-3’ 
TC2 5’-CACTCTGCCTTTCGACAGCGAAGCTGTCC-3’ 
TC3 5’-CACTCTGCCTCTTGACAGC-3’ 
TC4 5’-CACTCTGCCTTTCGACAGCG-3’ 
TC5 5’-CACTCTGCCTCTTGACAGCGAAGCTGTC-3’ 
TC6 5’-CACTCTGCCTTTCGACAGCGAAGCTGTC-3’ 
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Table 2.1C: FRET oligonucleotide sequences used herein 
Oligo Sequence 
EP 5'-PHOS-TTGAGGCAGAGTAGGACC-3' 
FP 5'-PHOS-TTTTTT TTG AGG CAG AGT AGG ACC-3' 
Tna 5'-GGTCCTACTCTGCCTCAA GACGGTCTGCTGCACTGG-3' 
TA 5'-GGTCC-TAMRAdT-ACTCTGCCTCAAGACGGTCTGCTGCACTGG-3' 
Tnd 5'-CCAGTGCAGCAGACCGTCC-3' 
Tnd2 5'-CCAGTGCAGCAGACCGTC-3' 
TD 5'-CCAG-FAMdT-GCAGCAGACCGTCC-3' 
TD2 5'-CCAG-FAMdT-GCAGCAGACCGTC-3' 
Sequences of individual oligonucleotides used. (PHOS): phosphate, (FAM): fluorescein, 
(BioTEG): biotin, (2-AP): 2-aminopurine and (TAMRA): tetramethylrhodamine. 
2.3.2 DNA constructs  
Table 2.2A: DNA kinetic constructs 
Construct Oligo Combination Description 
BD1 E1 + T3 5' FAM, blunt duplex 
BD2 E2 + T3 3' FAM, 5' phosphate, blunt duplex 
ND1 E1 + T4 5' FAM, nicked duplex 
ND2 E2 + T4 3' FAM, 5' phosphate, nicked duplex 
ND3 E2 + T4 3' FAM, 5' hydroxyl, nicked duplex 
OVH1 E1 + T5 5' FAM, 3' overhang 
OVH2 E2 + T5 3' FAM, 5' phosphate, 3' overhang 
OVH3 E4 + T5 5' phosphate, 3' overhang competitor 
PY1 F1 + T5 5' FAM, pseudo-Y 
PY2 F2 + T5 3' FAM, pseudo-Y 
PY3 Bio-psY 5' FAM, 5' biotin, unimolecular pseudo-Y 
SF1 E1 + T1 5' FAM, single flap 
SF2 E2 + T1 3' FAM, 5' phosphate, single flap 
SF3 E3 + T1 3' FAM, 5' hydroxyl, single flap 
DF F1 + T1 5' FAM, double flap 
DF2 F3 + T2a + T2b 5' FAM flap, 5' biotin (T2a and T2b), double flap 
The oligonucleotides (Table 2.1A) were form the substrate constructs in table 2.2A.  
 40 
 
The oligonucleotides (Table 2.1B) were form the substrate constructs in table 2.2B.  
Table 2.2C: DNA FRET constructs 
Construct Oligo Combination Description 
NDNL EP + Tna + Tnd2 Non-labelled, 5' phosphate, nicked duplex 
NDDOL EP + Tna + TD2 Internal FAM, 5' phosphate, nicked duplex 
NDAOL EP + TA + Tnd2 Internal TAMRA, 5' phosphate, nicked duplex 
NDDAL EP + TA + TD2 Internal FAM and TAMRA, 5' phosphate, nicked duplex 
DFNL FP + Tna + Tnd Non-labelled, 5' phosphate, double flap 
DFDOL FP + Tna + TD Internal FAM, 5' phosphate, double flap 
DFAOL FP + TA + Tnd Internal TAMRA, 5' phosphate, double flap 
DFDAL FP + TA + TD Internal FAM and TAMRA, 5' phosphate, double flap 
The oligonucleotides (Table 2.1C) were form the substrate constructs in table 2.2C.  
They were first incubated at 95°C for 5 minutes in 1×FB before cooling at room temperature 
to anneal. 
 
Table 2.2B: DNA ECCD constructs 
Construct Oligo 
Combination 
Description 
SF+1-1 EEC1 + TC1 5' phosphate, 2-AP +1-1 positions, single flap 
SF-1-2 EEC2 + TC2 5' phosphate, 2-AP -1-2 positions, single flap 
OVH+1-1 EEC1 + TC3 5' phosphate, 2-AP +1-1 positions, 3' overhang 
OVH-1-2 EEC2 + TC4 5' phosphate, 2-AP -1-2 positions, 3' overhang 
N+1-1 EEC1 + TC5 5' phosphate, 2-AP +1-1 positions, nicked duplex 
N-1-2 EEC2 + TC6 5' phosphate, 2-AP -1-2 positions, nicked duplex 
UOVH+1-1 UEEC1 5' phosphate, 2-AP +1-1 positions, unimolecular 3' overhang 
UOVH-1-2 UEEC2 5' phosphate, 2-AP -1-2 positions, unimolecular 3' overhang 
DF+1-1 FEC1 + TC1 2-AP +1-1 positions, double flap 
DF-1-2 FEC2 + TC2 2-AP -1-2 positions, double flap 
PY+1-1 FEC1 + TC3 2-AP +1-1 positions, pseudo-Y 
PY-1-2 FEC2 + TC4 2-AP -1-2 positions, pseudo-Y 
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Figure 2.2: Constructs used in kinetic experiments. A. Blunt duplex (BD) B. Nicked duplex 
(ND) C. 3' overhang (OVH) D. Pseudo-Y (PY) E. Biotinylated pseudo-Y (BioPY) F. single 3' 
flapped duplex (SF) G. double flapped duplex (DF) H. extended double flapped duplex (DF2). 
Reacting strands are highlighted in cyan and template strands are highlighted in brown (and 
purple for DF2). Ends highlighted in red (e.g. 3') indicate that multiple modifications are 
present for this constructs (see table 2.3.1b). For unique constructs the modifications for 
fluorescein and biotin are highlighted (F and B respectively).  
Figure 2.3: Constructs used for ECCD. Single 3' flapped duplex (SF), 3' overhang (OVH), 
nicked duplex (ND), unimolecular 3' overhang (UOVH), double flapped duplex (DF) and 
pseudo-Y (PY) constructs with tandem 2-aminopurine’s (in red) in positions +1-1 (A, C, E, 
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G, I, K) and -1-2 (B, D, F, H, J, L) respectively. The reacting strands are highlighted in cyan 
and the template strands are coloured in brown.   
Figure 2.4: Constructs used for FRET. The reacting strands are highlighted in blue, with the 
donor and acceptor strands highlighted purple and brown respectively. The nicked duplex (A) 
and double flapped duplex (B) with the site for the internal tetramethylrhodamine (purple) on 
the acceptor and internal fluorescein (red) on the donor. The labels are linked directly to 
carbon-5 of the thymine base. Presence of the labels is determined by the name; non-labelled 
(NL) has neither, donor-only labelled (DOL) and acceptor-only labelled (AOL) have the single 
label represented in the name and donor acceptor labelled (DAL), which contains both. In the 
absence of a label, the thymine remains.  
2.3.3 Purification of oligonucleotides 
Some 3'-fluorescein labelled oligonucleotides required further purification before they could 
be analysed by kinetics. This step was performed for oligonucleotides E1 and E2 to remove 
any traces of synthesis intermediates. Initial purification required isolation of the major peak 
by high pressure liquid chromatography (HPLC) which was run at 50⁰C to denature the DNA 
(therefore, dHPLC). Production of 1 M triethylammonium acetate was achieved by gently 
adjusting a solution of triethylamine to pH 7.0 on ice using acetic acid. This can be used to 
make the following buffers: 
Table 2.3: Oligo HPLC purification buffers 
HPLC Buffers Ingredients 
Oligo Purification  
Buffer A 
100 mM triethylammonium acetate pH 7.0, 0.025% acetonitrile 
Oligo Purification  
Buffer B 
100 mM triethylammonium acetate pH 7.0, 25% acetonitrile 
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Figure 2.5: HPLC gradient used for oligonucleotide purification. The gradient used for the 
dHPLC to isolate the major oligonucleotide product. 
Further purification was performed with a 5 mL DEAE HiTrap fast flow (FF) anion 
exchange column using the following buffers: 
Table 2.4: Oligo Desalting buffers 
DEAE Buffers Ingredients 
DEAE Buffer A  10 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.02% NaN3 
DEAE Buffer B 10 mM Tris, pH 7.5, 1 M NaCl, 1 mM EDTA, 0.02% NaN3 
Oligonucleotides were purified by an isocratic elution with 3 column volumes (CVs) 
of DEAE buffer B after loading of the sample onto a 5 mL HiTrap DEAE column (GE 
healthcare) pre-equilibrated with DEAE buffer A. The fractions containing DNA were pooled 
before desalting into deionised water using NAP-25 columns (Illustra, GE Healthcare) per the 
manufacturer’s instructions. Purity was determined by capillary electrophoresis. 
2.4 Multiple turnover kinetics 
2.4.1 Steady-state kinetics 
Steady state kinetics were performed with various DNA constructs and an appropriate enzyme 
concentration to produce between 10-20% product formation over a 20-minute timescale. 
Reactions were performed to a final concentration of 1×RRB with time points taken manually 
at 2, 4, 6, 8, 12, 16 & 20 minutes before being quenched in 250 mM EDTA. Samples were 
analysed by ion-paired reverse-phase denatured HPLC equipped with a fluorescence detector 
(Wave system, Transgenomic, UK). It should be noted that only experiments using 5' 
fluorescein-labelled substrates were examined by dHPLC. The chromatograms were 
integrated to determine the concentration of product formed at each time point (equation 2.1). 
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Initial rates of reaction (v, nM min-1) were then obtained using linear regression before 
conversion into the normalized rates (v/[E], min-1). 
Equation 2.1    [𝑃] = [𝑆]0𝑥
∫ 𝑃
∫ 𝑃+∫ 𝑆
 
Table 2.5: Wave dHPLC buffers 
dHPLC Buffers Ingredients 
Wave Buffer A 0.1% Acetonitrile, 1 mM EDTA, 2.5 mM tetrabutyl ammonium 
bromide 
Wave Buffer B 70% Acetonitrile, 1 mM EDTA, 2.5 mM tetrabutyl ammonium 
bromide 
Figure 2.6: HPLC wave gradient for kinetic substrates. The gradient used in dHPLC to 
separate products and substrate in kinetic reactions, in terms of the percent of wave buffer B. 
2.4.2 Steady state kinetics by capillary electrophoresis 
Experiments using constructs labelled with a 3' fluorescein cannot be examined by dHPLC 
due to the nature of exonucleolytic cleavage, which produces multiple products of similar size. 
Capillary electrophoresis (CE) is apt at separating nucleotides with single nucleotide 
resolution and was utilised for this role. Steady state kinetics were performed as before but 
samples were quenched in a solution of 98% formamide and 20 mM EDTA. Capillary 
electrophoresis was performed with the P/ACE MDQ Plus system (Beckman Coulter) using 
the ssDNA 100-R Kit (AB SciEx UK Limited) according to the manufacturer’s instructions. 
The supplied gel was injected into a 30 cm capillary (internal diameter (ID) of 100 μm) 
with a 20 cm length to detection window (LD) using 70 psi for 5 minutes. The gel was then 
equilibrated between two buffer vials containing the standard Tris-Borate-Urea buffer 
provided at 3, 5, and 9.3 kV with a ramp time of 0.17 minutes for 2, 2 and 10 minutes 
respectively. Samples were electrokinetically injected for between 4-8 s, preceded by a 1 s 
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water plug injection of deionised water. Separation of reaction intermediates was performed 
over 20 minutes at 9.3 kV, applied between the two buffer vials. Samples were analysed at 50 
⁰C with constant pressure of 40 psi applied to both sides of the capillary. The gel was replaced 
every 5-7 runs and buffer vials were replaced frequently (the more regularly the replacement, 
the greater the consistency in retention times). Peak detection was by laser induced 
fluorescence (LIF) using an excitation wavelength of 488 nm and a 520 nm filter to measure 
the emission. The electropherograms were integrated to determine the product concentrations 
(equation 2.1) and normalised rates were determined as above.  
2.4.3 Determination of Michaelis-Menten Parameters 
Michaelis-Menten parameters were determined by steady state kinetics and analysed by either 
dHPLC or CE depending on the construct (ND1 and ND2 respectively, see section 2.3).  
The normalised rates were determined as mentioned previously and fit to the following 
equation: 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 + [𝑆]
 
𝑊ℎ𝑒𝑛 [𝑆] = 𝐾𝑚   𝑡ℎ𝑒𝑛 
𝑣
[𝐸]
=
𝑘𝑐𝑎𝑡
2
 
𝑣 =
𝑉𝑚𝑎𝑥
2
 
Table 2.6: Concentrations for use in Michaelis-Menten kinetics analysis 
[S], nM ND1 [E], pM ND2 [E], pM 
1000 280 250 
750 210 210 
500 140 140 
250 70 70 
150 40 40 
100 28 28 
75 21 25 
50 14 20 
25 10 10 
20 - 10 
15 - 8 
12.5 - 7 
10 5 5 
5 3.5 4 
2.5 2 - 
1 0.8 - 
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𝑉𝑚𝑎𝑥 =  𝑘𝑐𝑎𝑡[𝐸] 
𝑣
[𝐸]0
=
𝑘𝑐𝑎𝑡[𝑆]
𝐾𝑚 + [𝑆]
 
2.4.4 Observation of reactions by denaturing polyacrylamide gel electrophoresis (PAGE) 
Denaturing PAGE gels were constructed in glass plates by the polymerisation of a buffer 
containing 7 M urea, 1×TBE and 20% acrylamide (19:1). The buffer is initially degassed 
before the addition of 10% ammonium persulphate (APS), to a final concentration ~0.05%, 
and N-, N-, N’-, N’- tetramethylethylenediamine (TEMED) to 1/10 the volume of APS, and 
~20% acrylamide. Enzyme reactions were quenched 1:1 with denaturing PAGE loading 
buffer, and heated for 2 minutes at 95⁰C immediately before loading. Gels were pre-run with 
1×TBE, until the gel is at 65⁰C. Samples were loaded onto the gel and run until the 
bromophenol blue (the first dye) reaches the bottom of the gel; these gels run optimally at 
55⁰C. The gels were imaged by a Biorad Chemidoc imager using fluorescence from the FAM 
labels. 
2.5 Single turnover kinetics 
Single turnover kinetics were performed with excess enzyme concentrations to substrate, and 
quenched over short time scales. Experiments were performed using a RQF-63 quench flow 
device (Hi-Tech Sci Ltd., Salisbury, UK).  
2.5.1 Determination of kST for hEXO1-352 
Experiments with hEXO1-352 were carried out once a Km was determined by steady state 
kinetics for ND1. Experiments were performed with 6.4 nM substrate concentration and either 
160 or 680 nM enzyme concentrations in 1×RRB. Samples were initially mixed 1:1 with the 
substrate and enzyme to a final concentration of 3.2 nM substrate and 80 or 340 nM enzyme 
(10×Km and 40×Km respectively). Mixtures were quenched with QF ST quench in the ratio of 
2:1 ([ES]:quench) and analysed by dHPLC equipped with a fluorescence detector. Time points 
were taken at 9.1, 12.1, 19.4, 27.6, 30.6, 40.8, 41.8, 57.5, 82.1, 124.2, 140.8, 240.8, 440.8, 
840.8, 1640.8, 3240.8, 6440.8, 12840.8, 25640.8 & 51240.8 ms and chromatograms were 
integrated to determine the percentage of product formation. Data was fit to a single 
exponential non-linear regression in Graphpad Prism using the following equation: 
Equation 2.2    𝑃𝑡 =  𝑃∞(1 − 𝑒
−𝑘𝑡) 
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Product formation (Pt) per unit time (t) are experimental values, and P∞ is the amount of 
product at the end point. 
2.5.2 Determination of threading by trapping and blocking with streptavidin 
Trapping and blocking experiments were performed using the PY3 substrate. Three types of 
reaction were performed; a premixed state acting as a streptavidin (SA)-free control, a trapped 
state where SA traps the substrate onto the enzyme, and a blocked state with the substrate 
blocked from enzymatic reaction. Reactions were performed with 1-8 μM hEXO1-352 and 10 
nM substrate, which were pre-equilibrated in SA reaction buffer containing either 2 mM 
calcium ions or EDTA.  
EXO1 and the substrate were pre-incubated for two minutes at 20⁰C, for the premixed 
and trapped states, before the addition of 1×SA-RB (for the premixed state) or five equivalents 
of SA (for the trapped state) and a further incubation period of five minutes. In the case of the 
blocked state, the substrate and five equivalents of SA were pre-incubated for five minutes at 
20⁰C before the addition of enzyme and a further 2 minute incubation period. After pre-
incubation, reactions were heated to 37⁰C before initiation with the addition of SA-RB 
containing 16 mM magnesium ions in the ratio of 1:1.  
The reactions were sampled manually (between 15 s and 30 hrs) or by using a RQF-
63 quenched flow device (between 9.1 ms and 60 s) (Hi-Tech Sci Ltd., Salisbury, UK). 
Reactions were quenched 2:1 with 8 M urea containing 300 mM EDTA, pH 8.0. A true zero 
time point was taken to determine whether reaction occurred before Mg2+ addition, which 
showed only ~1% product formation from pre-incubation. Samples were analysed by dHPLC 
equipped with a fluorescence detector and chromatograms were integrated to determine the 
product formation. Data were fit to either a single (equation 2.2) or double (equation 2.3) 
exponential non-linear regression in Graphpad Prism. 
Equation 2.3    𝑃𝑡 = 𝐴1𝑃𝐴(1 − 𝑒−𝑘1𝑡) + 𝐴2(100 − 𝑃𝐴)(1 − 𝑒−𝑘2𝑡)  
Product formation (Pt) per unit time (t) are experimental values and PA is the amount of product 
at the end point of the first phase. A1 and A2 represent the amplitudes of the two equations 
respectively. 
 49 
 
The larger flap of PY3 (see section 2.3) required an extended gradient for effective 
elution with samples containing SA. The following gradient was used: 
Figure 2.7: Extended dHPLC gradient used for the biotinylated substrate. The gradient used 
for the dHPLC to elute all traces of SA, in terms of the percent of wave buffer B. 
2.6 Circular dichroism spectroscopy 
Samples were prepared in CDRB with 10 μM substrate and 12.5 μM enzyme where 
appropriate. Once assembled, CD spectra (300-480 nm) were acquired at 20⁰C using a 
Chiralscan Plus spectrophotometer (Applied photophysics). Spectra were taken using a quartz 
cuvette with a 5 mm pathlength. After spectra of samples containing 10 mM CaCl2 were taken 
(the standard CDRB), they were supplemented with EDTA to a final concentration of 23.8 
mM and another spectra was taken.  
CD spectra traces were recorded in 0.75 nm steps (for between 380-480 nm) and 0.5 
nm steps (for between 300-380 nm), with 0.5 seconds per step and two spectra being taken. 
Blanks were taken in the absence of substrate and enzyme to determine a baseline. Spectra 
were baseline-substracted before gentle correction by smoothing using the Savitsky-Golay 
filter to a window size of 10. Spectra were converted from CD (mdeg) into molar ellipticity, 
and entered into an Excel spreadsheet. Data were normalised to account for baseline-shift 
between 400-480 nm, where no signal from the 2-AP is present. Normalised data were plotted 
in Graphpad Prism as Δε per mol 2-AP residue versus the wavelength.  
 
 50 
 
2.7 Förster resonance energy transfer and fluorescence anistropy 
2.7.1 Förster resonance energy transfer (FRET) 
Measuring the enhancement of fluorescence of the acceptor dye at 37⁰C allowed for 
determination of FRET efficiencies by the (ratio)A method [109]. Samples containing 10 nM 
of trimolecular NL, DOL or DAL substrates were titrated with increasing concentrations of 
enzyme and traces were recorded using a Horiba Jobin Yvon FluoroMax-3 fluorometer 
(Horiba, Ltd). The donor label (FAM) was excited at 490 nm (with a 2 nm slit width) and 
emission was measured over the range of 515-650 nm (with a 5 nm slit width). For the acceptor 
label (TAMRA), the sample was excited at 560 nm (with a 2 nm slit width) before 
measurements of the emission were taken between 575-650 nm (with a 5 nm slit width). 10 
nM substrate was made up in FRET RB supplemented with 1 mM DTT; samples were then 
equilibrated to 37⁰C by a 10 minute incubation period. The first emission was taken prior to 
the supplementation of enzyme; enzyme was then added in increasing concentrations with 
spectra being taken with each step, and corrections made for substrate dilution. The NL sample 
spectra were subtracted from other spectra, acting as a background for the changing 
concentrations of buffer and enzyme. 
Transfer efficiencies were determined using the following equations: 
Equation 2.4      𝐸 = (𝑟𝑎𝑡𝑖𝑜)𝐴/ (
∈𝐷(490)
∈𝐴(560)
) − (
∈𝐴(490)
∈𝐴(560)
) 
Where 
Equation 2.5     (𝑟𝑎𝑡𝑖𝑜)𝐴 =  
𝐹𝐷𝐴(𝜆𝐸𝑋
𝐷 ,𝜆𝐸𝑀
𝐴 )−𝑁∙𝐹𝐷(𝜆𝐸𝑋
𝐷 ,𝜆𝐸𝑀
𝐴 )
𝐹𝐷𝐴(𝜆𝐸𝑋
𝐴 ,𝜆𝐸𝑀
𝐴 )
 
And 
Equation 2.6     𝑁 = 𝐹𝐷𝐴(𝜆𝐸𝑋
𝐷 , 𝜆𝐸𝑀
𝐷 )/𝐹𝐷(𝜆𝐸𝑋
𝐷 , 𝜆𝐸𝑀
𝐷 ) 
Eqt 2.7 𝐸 = 𝐸𝑚𝑖𝑛 +
(𝐸𝑚𝑎𝑥− 𝐸𝑚𝑖𝑛)
2[𝑆]
[([𝑆] + [𝑃] + 𝐾𝑏𝑒𝑛𝑑) − √([𝑆] + [𝑃] + 𝐾𝑏𝑒𝑛𝑑)2 − 4[𝑆][𝑃]] 
Where FDA and FD represent the emission of the DAL and DOL respectively, at their 
given wavelengths (e.g. 𝐹𝐷𝐴(𝜆𝐸𝑋
𝐷 , 𝜆𝐸𝑀
𝐴 ) represents the emission of the acceptor when the donor 
label is excited; therefore named DAL). The molar absorption coefficients of the donor and 
acceptor at the given wavelengths are represented by εD and εA. The absorbance spectra of the 
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DAL and AOL are taken to determine the εD(490)/ εA(560) and εA(490)/ εA(560) respectively. 
The energy transfer efficiency (E) was fitted in the Kaleidagraph program (Synergy software) 
using a nonlinear regression (equation 2.7). The minimum and maximum energy transfer 
values, Emin and Emax; [S] and [P] are the substrate and protein concentrations respectively. The 
bending equilibrium dissociation constant of the protein substrate [PS] complex is represented 
by Kbend.   
2.7.2 Fluorescence anisotropy (FA) 
The dissociation constant, KD, was also determined by the Horiba Jobin Yvon FluoroMax-3 
fluorometer using fluorescence anisotropy with automatic polarisers. Experiments were 
performed using the DOLND and the 3' ND constructs mentioned previously. The experiments 
were performed in a similar way to FRET; initially samples with 10 nM substrate in FRET 
RB at 37⁰C, with enzyme being titrated into the cuvette and points being taken with increasing 
concentrations of enzyme. Six measurements of IVH, IVV, IHV and IHH were recorded in 1 minute 
time courses for each concentration of enzyme, with a control being taken prior to enzyme 
supplementation. The measurements were used to calculate anisotropy (r) in the following 
equation: 
Equation 2.8     𝑟 =
𝐼𝑉𝑉−𝐺𝐼𝑉𝐻
𝐼𝑉𝑉−2𝐺𝐼𝑉𝐻
 
The intensities of the vertical and horizontal components of the emitted light using 
vertically polarised excitation is represented by IVV and IVH respectively. G is a correction factor 
using the inverse intensities of the vertical and horizontal components of the emitted light that 
is horizontally polarised, IHV and IHH, for the difference in response of the detector to vertical 
and horizontal polarised light and is expressed by the equation: G = IHV/IHH. The total 
fluorescence, ITOT, in the absence of polarisers was also measured. Data was fit in 
Kaleidagraph using a similar nonlinear regression to equation 2.7. The FRET efficiency (E) 
is replaced by anisotropy (r), and the Kbend constant is replaced by the KD.  
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2.8 Inhibitor studies 
The compounds used in this section were provided by Astra Zeneca to determine their ability 
to inhibit FEN1 and their specificity for the enzyme were the project of another student in the 
Grasby group [110]. The compounds were derivatives of previously identified inhibitors of 
hFEN1 [111-112] and are shown below: 
Figure 2.8: N-hydroxyurea compounds. The athersys, cyclopropylmethyl and 4-
methoxybenzyl N-hydroxyurea compounds, 1, 2 and 3 respectively. 
Studies were performed on hEXO1-352 to determine whether compounds 1 and 2 were 
specific to hFEN1 or if they affected other family members. The ability for hFEN1 to process 
the single flap was also tested with compounds 1 and 2. Other kinetic experiments tested the 
effects of compounds 1 and 3 on proliferating cell nuclear antigen (PCNA) stimulation of 
hFEN1 with a double flapped substrate. 
2.8.1 Multiple turnover studies 
Studies were performed as explained in section 2.4.1 but with the addition of the compounds. 
The compounds were dissolved in 100% dimethyl sulphoxide (DMSO) and supplemented into 
the final enzyme dilutions and the reaction mixture in the ratio of 1:100, to a final 
concentration of 1% DMSO. The compound-free control is supplemented in the same way 
with 100% DMSO to a final concentration of 1% DMSO. Reactions were performed with 150 
nM of SF1 and OVH1 (see section 2.3) with hFEN1 and hEXO1-352 respectively; with the 
concentrations of enzyme and the compounds (1 and 2) shown in table 2.7. 
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Experiments to show the effects of compounds 1 and 3 on FEN1 stimulation with 
substrate DF2 (see section 2.3). These experiments were performed by supplementing the 
reaction mixture with increasing concentrations of PCNA, with a PCNA-free control. The 
concentrations tested were 0, 0.1, 1 and 10 μM PCNA (it should be noted that this is the trimer 
concentration). In each case the concentrations of the substrate, compound and enzyme were 
50 nM, 10 μM and 150 pM respectively. Samples were run as described in section 2.4.1. An 
IC50 was determined for the DF2 with compound 1 prior, to determine enzyme concentrations. 
2.8.2 Differential scanning fluorimetry (DSF)  
To determine whether an interaction is present between the compounds and the enzymes, 
differential scanning fluorimetry (DSF) was performed. Thermal shifts were acquired with 2.5 
μM of hFEN1 or hEXO1-352 in 1×RRB supplemented with 25 mM EDTA or NaCl with 
increasing concentrations of compounds 1 or 2. A temperature ramp between 25-95⁰C was 
performed, with steps of 1⁰C taken, and changes in the stability were detected by use of Sypro 
Orange at 610 nm (excitation 492 nm). The data was converted into the average change in 
melting temperature (ΔTm) and plotted against the concentration of the compounds using 
Graphpad Prism. If the melting temperature increases in the presence of a compound it 
suggests an interaction is occurring. 
 
 
 
 
 
Table 2.7: Concentrations of compounds and enzymes used in inhibition experiments 
Compound concentration (nM) hFEN1 [E] (pM) - SF1 hEXO1 [E] (pM) hFEN1 [E] (pM) - DF2 
10000 2500 20000 150 
5000 - - 100 
1000 750 2000 70 
500 400 - 40 
100 150 200 25 
50 100 - 20 
10 40 - 15 
5 - - 10 
0 30 200 8 
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Chapter 3: Studies into the Specificity and Kinetic Parameters of 
Exonuclease 1 as an Exonuclease 
Human EXO1-352 (truncated at 352 amino acids) is termed hEXO1 from this point onwards 
and was expressed via the lac operon using autoinduction media [108] in Escherichia coli. 
The bacterial cells were harvested and lysed by freezing at -20 ⁰C. Once defrosted on ice, the 
lysate was sonicated and centrifuged to separate the soluble and insoluble fractions. The 
isolated soluble fraction, or supernatant, was first loaded onto a cobalt metal-affinity column 
to selectively capture the protein by its 6-His tag. The eluate sample was further purified by 
cation exchange column, isolating the positively charged protein and removing the negatively 
charged DNA. After removal of the 6-His tag with the TurboTEV protease (Bioscience, Ltd), 
EXO1 was isolated by removal of TEV from the solution by MagneGST beads (Promega 
Corporation). Finally, the sample was desalted into 2× storage buffer followed by 
concentration of the protein to an appropriate concentration and dilution to 1× storage buffer 
with 50% glycerol and storage at -20 ⁰C, ready for kinetic studies. 
3.1 Evaluation of the substrate specificity of hEXO1 
In the repair pathways discussed in chapter 1, great diversity in the substrate of exonuclease 1 
(EXO1) was observed compared to other superfamily members with both exo- and endo-
nucleolytic capabilities. Briefly, in mismatch repair, the key substrate is a nicked duplex, 
whereas in double strand break repair, EXO1 cleaves 3' overhang substrates generated by 
treatment with the MRN complex; or, in the absence of this complex, overexpression of EXO1 
has also been shown to cleave blunt-ended duplexes [54]. Therefore, a screen of DNA 
constructs was performed to determine the preferred exonucleolytic substrate of EXO1. The 
substrates used in this study are shown below in figure 3.1. 
Initial tests of hEXO1 were performed using denaturing PAGE to analyse how 
substrates are processed. Assays with 3'- (OVH2) or 5'-labelled (OVH1) substrates were 
performed with 150 nM substrate and 1 or 5 nM hEXO1 respectively. Samples were quenched 
at 0-20 minutes, and run on a 20% gel (figure 3.2A). Reactions of the same constructs with 
200 pM hEXO1 were analysed by the dHPLC and shown in figure 3.2B-C. 
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Figure 3.1: DNA constructs. The various substrates screened with hEXO1 to determine its 
specificity. With 5' (top) and 3' (bottom) FAM labelled constructs.  
Figure 3.2: Initial kinetic tests of hEXO1 with 5'- and 3'-FAM labelled constructs. Kinetic 
assays of a 3' overhang substrates analysed by 20% denaturing PAGE (A) or dHPLC 
equipped with a fluorescence detector (B-C). A. Lanes 1-5 contain an assay of 1 nM hEXO1 
with 150 nM OVH2, and correspond to time points 4, 8, 12, 16 and 20 minutes (blue 
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numbering above the lanes). Lanes 6-11 are an assay of 5 nM hEXO1 with 150 nM OVH1, 
and correspond to time points 0, 4, 8, 12, 16 and 20 minutes (blue numbering above the lanes). 
The end lane is a 3'-fluorescein (FAM) labelled nucleotide standard containing 1, 3, 5, 7, 9, 
11, 13, 15 and 17 nucleotides. It should be noted that 5'-FAM labelled nucleotides travel 
slower than their respective 3'-FAM labelled alternatives. B-C. 200 pM hEXO1 with 150 nM 
of OVH2 (B) and OVH1 (C), with time points 0, 2, 4, 6, 8, 12, 16 and 20 minutes which are 
colour coded in the figure. For details on the DNA substrates used see section 2.3.  
Experiments with 150 nM of the blunt duplex (BD1), 3' overhang (OVH1) and nicked 
duplex (ND1) substrates were assayed with 1000, 200 and 40 pM enzyme respectively. 
Samples were analysed by dHPLC equipped with a fluorescence detector, and the 
chromatograms were integrated manually to calculate the initial rate of reaction. However, to 
determine whether the 5'-fluorescein label acts innocently, meaning the FAM has no effect on 
the enzymes catalysis, DNA constructs with 3'-fluorescein labels were tested. As before, 150 
nM of BD2, OVH2 and ND2 were assayed with 40 pM of enzyme (for details on substrates 
section 2.3). Quenched 3'-labelled samples were analysed by capillary electrophoresis, and 
integrated manually like with the 5' samples. The results are shown in figure 3.3. 
 
 
Figure 3.3: Exonucleolytic multiple turnover data. A. A graph of the multiple turnover data, 
with both 5' FAM (red) and 3' FAM (blue) respectively. B. The exact numbers plotted in the 
graph. The fold difference against the 5' FAM is also shown.  
The data show that the nicked duplex displays a similar rate between the two labels 
(~0.6×), with the overhang substrates demonstrating a 3-fold difference and a 25-fold 
difference for the blunt duplex. The differences in the nicked duplex and overhang are not 
significant. However, the observed differences with the blunt duplex labelled substrates may 
be due to the lack of upstream region in this construct; lack of contacts with the α2-3 
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hydrophobic wedge may reduce the ability to thread the 5'-FAM into the active site. This 
hypothesis is only postulated. Due to the consistency of rates between the 3' and 5' FAM 
labelled nicked duplex substrates, this construct was selected as the preferred substrate and 
the Michaelis-Menten parameters were determined. 
3.2 Determination of the steady state parameters 
The steady-state parameters were determined using the ND1 and ND2, over a range of 
substrate concentrations. Samples were assayed with an appropriate enzyme concentration to 
produce ~10% product by 10 minutes (exact concentrations are listed in section 2.4.3). 
Constructs with 5'- (ND1) and 3'-FAM (ND2) were analysed by dHPLC and CE respectively. 
Chromatograms and electropherograms were integrated and converted into normalised rates 
before fitting by non-linear regression to the Michaelis-Menten equation in Graphpad Prism 
(GraphPad Software, Inc) (figure 3.4A). The residual plot shows no correlation, adding to the 
validity of the fits (figure 3.4B).  
 
Figure 3.4: Determination of the steady state parameters. A. The Michaelis-Menten fit of the 
ND1 (red) and ND2 (blue) substrates with hEXO1. B. The residual plot of the two fits, colour 
scheme as before. C. The parameters determined by the Michaelis-Menten fit (Km and kcat) 
and the kcat/Km, with FEN1 data from a colleagues thesis for comparison [110].  
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The normalised rate (v/[E]0) of Michaelis-Menten redefines the equation as follows: 
𝑣
[𝐸]0
=
𝑘𝑐𝑎𝑡[𝑆]
𝐾𝑚 + [𝑆]
 
Where the Km is the substrate concentration needed for half the enzyme to bind the 
substrate, and therefore, half the enzyme’s max rate. The maximal rate constant, otherwise 
known as the turnover number, defined as kcat, is the reciprocal time (e.g. min
-1), and 
characterises the number of catalytic cycles (or “turnovers”) the enzyme can undergo in one 
unit of time (e.g. one minute). When the Km is equal to the [S], the v/[E]0 becomes equal to 
half the kcat. Whereas, when the [S] is much higher than the Km, the Km becomes negligible. 
This results in the v/[E]0 being approximately equal to the kcat. However, the kcat can not truly 
be reached due to its nature. The v/[E]0 then represents the plateau of the fitted curve.  
The Km values for EXO1 (with the 5' and 3' FAM substrates) and also for FEN1 are 
relatively low and suggest that both enzymes reach their maximal rates at low concentrations 
of substrate. The turnover number, the kcat, for the 5' and 3' FAM labelled nick constructs with 
hEXO1 is around 25 min-1 , which is 6 times lower than hFEN1 with the double flap substrate. 
This means that the enzyme does not process its substrate as quickly as hFEN1 and suggests 
that hFEN1’s mechanism is more efficient due to both enzymes having similar Km values.  
The specificity constant, kA, which can be represented by kA ≡ kcat/Km, represents the reaction 
at low substrate concentrations. An enzyme is considered to be reaching catalytic perfection 
if its specificity constant is above 108 M-1 s-1, and the rate-limiting step becomes substrate 
diffusion into the active site. In the case of hFEN1 the specificity constant is 1.43 x 109 M-1 s-
1, which is above this marker for catalytic perfection. This result has been backed up by 
Brønsted-Lowry analyses with differing groups at 2' of the ribose sugar, which alters the pKa 
of the 3' oxygen which is part of the phosphodiester bond. In the case of hFEN1 Brønsted-
Lowry experiments showed no change in the reaction rate with differences in the pKa, which 
suggests that the chemistry step is not rate limiting, which is also observed for T5FEN [113-
114]. Whereas, viscogen studies using sucrose and glycerol showed a reduction in the rate of 
reaction, which could be due to disruption of the diffusion of substrate into the active site by 
the presence of a viscous environment. More work may be required, but it provides good 
evidence that hFEN1 is diffusion-limited [115].  
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On the other hand, hEXO1 has specificity constants below 108 M-1 s-1, and is unlikely 
to be diffusion-limited, although no Brønsted-Lowry analyses or viscogen studies have been 
performed on the enzyme as of yet. The specificity constant is limited by the Km, which has 
evolved to be similar to the substrate concentration that is naturally encountered in the 
enzymes system. The value of catalytic perfection is used in defining single-substrate 
reactions; hFEN1 primarily works efficiently on specific flapped substrates and nothing more. 
Whereas hEXO1 is present in multiple systems and targets a range of substrates, therefore 
ideas of catalytic perfection may not be broad enough to encompass this enzyme. There is also 
the possibility of processivity, which will be addressed later in this chapter.  
3.3 The mechanism of reaction and determination of the single turnover parameters 
The turnover number is a broad number that represents a large part of the reaction mechanism 
from the enzyme-substrate complex to the product release step. Single turnover kinetics relies 
on assaying low concentrations of substrate with excess enzyme. The principle of the 
experiment is for each substrate to be cleaved by a unique enzyme molecule, this means that 
the single turnover rate (kST) does not correspond to the product release step. The King-Altman 
diagram of the reaction mechanism is shown in figure 3.5. 
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Figure 3.5: Reaction scheme expected for FEN superfamily members. The reaction scheme 
of FEN enzymes starting with enzyme (E) binding to the substrate (S) to form the enzyme-
substrate complex (ES) with the substrate binding and release rates (kon and koff). A 
conformational change is postulated to occur forming ES', with the rate of this change and its 
reverse (kCC and kRCC), before the substrate is cleaved producing product (P) and creating the 
enzyme-duplex complex (EQ) with the chemistry rate (kchem) which is unlikely to be reversible. 
Finally, the rate of product release (krelease) with the reverse rate corresponding to the product 
association (kPA) which is more likely to occur with hEXO1 as some products are also 
substrates. The orange line represents the parts of the mechanism that account for the kcat and 
the purple line corresponds to the parts of the mechanism that account for the kST. 
  Therefore, single turnover kinetics represents the conformational change and 
chemistry steps of the reaction scheme. Parameters were determined for 3.2 nM ND1 substrate 
with either 10× or 40× Km enzyme concentration (80 and 340 nM) and assayed using quench 
flow apparatus over multiple time points. Two enzyme concentrations were used to ensure 
that the substrate was completely saturated. Experiments performed in figure 3.6A used the 5' 
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fluorescein-labelled nicked duplex, and were analysed by dHPLC. The resulting data were fit 
to a single exponential and plotted in figure 3.6 using equation 3.1. However, the data also fits 
to a double exponential which may be representative of the conformational change postulated 
for hEXO1, or due to some other factor.  
Equation 3.1    𝑃𝑡 =  𝑃∞(1 − 𝑒
−𝑘𝑡) 
Figure 3.6: The single turnover results. A. The single exponential fits for single turnover 
experiments with 10×Km (red) and 40×Km (blue) enzyme concentrations with 3.2 nM ND1 (see 
section 2.3). B. The parameters from the logarithmic fits, highlighting that there is a 10-fold 
difference between the kST and kcat. C. This result suggests that the release step is rate limiting, 
as it is the only difference between these two rates. 
As highlighted by figure 3.6B, the kcat is 10-fold lower than the kST, therefore the 
product release step is rate limiting. Due to the products of hEXO1 also being substrates the 
slower rate of reaction under multiple turnover conditions may in part be a result of the product 
repositioning into the active site before the next round of cleavage. An enzyme of this nature 
is considered processive, which will be discussed in the next section.  
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3.4 The implications of processivity in the mechanism of hEXO1 
Processivity is a phenomenon that is observed quite commonly in DNA polymerases, where 
they synthesise the DNA strand in one continuous process. The definition in terms of a 
nuclease, is for further available phosphodiester bonds to be processed before the product 
(which is also a substrate) is dissociated. A reaction mechanism describing this concept is 
shown in figure 3.7. 
 Figure 3.7: An extended reaction scheme to account for processivity. A. The reaction 
mechanism diagram with kcat and kST highlighted with orange and purple line respectively; this 
is the standard reaction mechanism. The extended scheme allows for the duplex products to 
remain bound and continue to be processed, with the ability to be released after every cleavage 
event depending on the strength of the processive nature of hEXO1. As above, the enzyme is 
defined by E. The substrate is represented by S with the number of nucleotides that have been 
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removed by n (where n is 0 nucleotides removed). The product is simply P with the nucleotide 
number added (same for the rates). B. A substrate schematic representing a nicked duplex 
after 1, 2 and 6 cleavage events (represented by n for the number of nucleotides). For both A 
& B this process can be continuous until all cleavable nucleotides are removed.   
 In vivo, hEXO1 is a processive enzyme, which can be facilitated by its protein partners 
[116]. The ladder nature of the 3'-FAM labelled samples in figure 3.2 suggests some 
processivity may take place in the absence of protein partners. An efficient processive enzyme 
would show only two bands on a gel, corresponding to the substrate and product; with every 
nucleotide being removed before the substrate is released. Samples labelled with the 3'-FAM 
tested by capillary electrophoresis show multiple bands forming at once, but it is unclear 
whether the products are preferred over the original substrate. The enzyme is considered to be 
mildly processive in vitro.  
The best way to test the hypothesis would be to perform single turnover with the 3' 
fluorescein labelled nicked duplex. However, this has not been successful for a combination 
of reasons. The capillary electrophoresis apparatus required to analyse 3' FAM labelled 
exonucleolytic reactions injects samples electrokinetically. Samples with small amounts of 
substrate are heavily affected by salt concentrations, which prevent efficient injection. The 
large enzyme concentrations also have an effect on this injection. Attempts to desalt samples 
with spin columns showed it to be a viable technique; however, it is not economical with the 
amount of samples required.  
Further experiments with ethanol precipitation have shown some success but it is 
unclear whether this technique is quantitative of all nucleotide sizes or whether smaller 
products are lost. It has been shown that the addition of glycogen to ethanol precipitation is 
effective at providing a quantitative range of products [117]. However, glycogen has an effect 
on the injection. Another approach where samples were treated with proteinase K has been 
successful and could provide an effective strategy in the future with further optimisation. No 
other experiments have been performed to study whether hEXO1 is processive, but they have 
been considered for future work.  
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3.5 Summary of exonuclease studies 
The preferred substrate of hEXO1 was determined to be the nicked duplex, which gave 
consistent catalytic parameters with 3' and 5' fluorescein labels. The 3' overhang substrate is 
also relatively consistent between the two labels, whereas the blunt duplex has an 
approximately 25-fold difference depending on the position of the label. The nicked duplex 
was selected and Michaelis-Menten parameters were determined for both the 5' and 3' FAM 
constructs. The Km was only 2-fold different between the 5'- (ND1) and 3'-FAM (ND2) (7.9 
and 17.5 nM respectively). The kcat is the same for the two labels (~25 min
-1).   
Studies with the nicked duplex using quenched flow kinetics to determine the single 
turnover parameters demonstrated that the average kST is roughly 10-fold higher than the kcat. 
This suggests that product release is rate limiting, due to single turnover kinetics relying on 
each substrate being processed by a unique enzyme molecule. Another hypothesis for this 
difference in rate is the idea of processivity, whereby other phosphodiester bonds are broken 
prior to product release. This is not measured by the determined kST as the 5'-FAM labelled 
construct (ND1) tested only represents the first cleavage. Therefore, continual cleavage of the 
substrate after the first nucleotide is removed could also be limiting. In any case, the difference 
between single and multiple turnover reactions implies high affinity for the product despite 
the question of whether the product then undergoes further reaction being incompletely 
resolved. 
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Chapter 4: Mechanistic Studies into how Flapped Substrates are 
Processed by EXO1 and FEN1 
4.1 Studies of the endonuclease capability of hEXO1 
The endonucleolytic (endo) capability of hEXO1 has been suggested to act as a back-up for 
hFEN1 in Okazaki fragment maturation, acting as an endonuclease to remove the flapped 
junctions generated in lagging strand synthesis. The nucleolytic cores of the two enzymes are 
similar with the major difference between them being a 3' flap binding pocket in FEN1. 
Without the binding pocket EXO1 may not bind substrates as efficiently; this may explain 
why FEN1 knockouts are lethal, suggesting that hEXO1 is not perfectly redundant.  
To determine whether the endo ability of hEXO1 is significant, tests were performed 
with a flapped pseudo-Y (PY) substrate. Experiments were performed as with the exo 
substrates at 150 nM of the PY1 (5' FAM labelled), PY2 (3' FAM labelled) and PY3 (referred 
to as the 5' FAM unimolecular substrate in figure 4.1) substrates with 0.2, 0.2 and 0.5 nM 
enzyme concentrations respectively. Due to the size of the endonucleolytic products, all 
samples could be separated by dHPLC, however, similar rates were obtained when analysing 
samples by CE. Initial rates were determined by integration of separated peaks before 
normalisation by the enzyme concentrations. The results are plotted in figure 4.1 alongside the 
nicked duplex data.  
An interesting observation of the pseudo-Y experiments is that multiple product peaks 
are formed when assayed with EXO1 (figure 4.2B). The nucleotide sizes of these peaks were 
determined by the addition of nucleotide standards of known sizes in dHPLC. The 
chromatograms of hEXO1 with the 5'-FAM labelled ND1 and PY1 substrates are shown 
below. In the case of the nicked duplex, a single product peak forms that localises as a single 
nucleotide product. Whereas, for the flapped PY, three product peaks form that localise to 4, 
5 and 6 nucleotide products. These sizes were determined with 5' FAM labelled nucleotide 
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standards being directly spiked into enzyme reactions. The chromatograms are displayed in 
figure 4.2. 
Figure 4.1: Examination of the endonucleolytic capability of hEXO1. A. A graph of the 
nicked duplex data previously shown in figure 3.1 alongside the pseudo-Y data. With 5' FAM 
labelled (red), 3' FAM labelled (blue) and PY3 (purple). No unimolecular nicked duplex has 
been tested. The graph demonstrates the significant difference between the two constructs, 
which is removed by use of a unimolecular construct, where only one reaction site is available. 
B. The initial rates of the nicked duplex and pseudo-Y with the two labels and the unimolecular 
form (for PY). A 10-fold difference is observed between the 5' FAM labelled unimolecular and 
bimolecular PY constructs. C. A schematic of the reaction sites between the bimolecular (i) 
and unimolecular (ii) constructs, highlighting that the enzyme can cleave the template strand 
in the bimolecular substrate. 
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Figure 4.2: The chromatograms of hEXO1 with the ND1 and PY1. A. ND1 forms a single 
18 nucleotide substrate peak and a single nucleotide product peak. The substrate with its 
possible cleavage site and the product peak are shown. B. PY1 forms three products: 4, 5 and 
6 nucleotides from left to right, with the large substrate peak on the right. The substrate 
therefore has three cleavage sites shown with arrows. These experiments were performed by 
multiple turnover and analysed by dHPLC. 
Multiple product peaks are expected for exo substrates (substrates processed from the 
end of the DNA strand) with a 3'-FAM label, as each product is a substrate. Similarly, multiple 
products are observed for endo 3'-FAM labelled substrates (substrates cleaved within the DNA 
strand); for example, multiple products form for the 3'-FAM labelled PY constructs, which are 
probably due to products being treated exonucleolytically after initial endonucleolytic 
reaction. However, it is not expected to be visible for the 5'-FAM labelled PY construct. As 
EXO1 can only cut within the flap it suggests that enzyme does not precisely cleave flapped 
substrates. A comparison of the exonucleolyic and endonucleolytic data for EXO1 and FEN1 
is shown in figure 4.3. 
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Figure 4.3: A comparison of the reaction mechanisms of hEXO1 and hFEN1. Rates of the 
exonuclease (A) and endonuclease (B) capabilities of hEXO1 (blue) and hFEN1 (red) 
normalised (normalisation was performed by dividing the rates by the ND1 EXO1 data (figure 
3.2) for exo constructs or by the PY1 EXO1 data (figure 4.1) for the endo constructs). The 
constructs examined are BD1, OVH1, ND1, SF1, PY1 and DF1 (see section 2.3). The graphs 
demonstrate that the exonucleolytic capabilities of the two enzymes are similar, but the 
endonucleolytic capabilities of hFEN1 are much greater than that of hEXO1 (around 90-fold).  
The exonucleolytic and endonucleolytic data for hEXO1 and hFEN1 were normalised 
by the rate of the nicked duplex data (for the exo data – figure 3.2) and the pseudo-Y data (for 
the endo data – figure 4.1) in figure 4.3.  Surprisingly the exo capability of the two enzymes 
is relatively equal, with the single 3'-flap being processed by FEN1 with a similar rate to 
EXO1. Alternatively, the endo capability of FEN1 is much higher than that of EXO1, with 
roughly a 90-fold drop in rate. However, the PY data used in this representation is made up of 
two separate strands (PY1), and it has been shown in figure 4.1 that a unimolecular pseudo-Y 
(PY3) has a 10-fold higher rate. Still, the hFEN1 endo rate would be roughly 10-fold higher 
than that of hEXO1, which can be explained by its preference for endo activity. However, the 
exo rate of the two enzymes are relatively equal. Further studies to determine whether the endo 
activity of the two enzymes follows a similar mechanism were then performed. 
4.2 Determination of hEXO1’s requirement to thread flapped substrates 
The endonucleolytic capability of these enzymes are aimed at targeting flapped structures; for 
example a 5'-flap for EXO1 or a double flapped junction in the case of FEN1. These enzymes 
endeavour to remove the flap efficiently; for FEN1 this is a precise process whereby a single 
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product is produced one nucleotide into the duplex. However, for EXO1 this is not a specific 
process as discussed previously. How these enzymes process flapped substrates was formerly 
an area of controversy, with suggestions of a clamping or threading mechanism of flap 
alignment. However, as mentioned in the introduction, the true nature of positioning the flap 
in the active site has been well studied in hFEN1 over the years and the mechanism of 
threading has been identified as the likely candidate. 
 Past studies relied on directly trapping a DNA substrate through the helical archway 
discussed in section 1.4. Substrates with a biotin modification at the end of a 5' flap were 
utilised for this experiment. A tetramer of streptavidin forms a high affinity stable interaction 
with the biotin molecule; in this case the streptavidin could either block the enzyme from 
processing the flap, or trap the substrate onto the enzyme depending on the order of addition.  
 The results showed that for both human and bacteriophage T5FEN homologs bound 
biotinylated substrate can effectively be trapped on the enzyme by streptavidin if the 
streptavidin is added after the formation of the enzyme substrate complex; if reaction is 
initiated this substrate decays very quickly analogously to the reaction of an unmodified 
substrate. Substrate can also be successfully blocked from threading by adding streptavidin 
prior to interaction with the FEN protein; this produces a slow reaction rate [101]. This study 
was backed up with competition experiments, supplementing with an excess of unlabelled 
substrate after the enzyme is trapped with streptavidin or simply premixed (in the absence of 
streptavidin). Addition of competitor produced a clear drop in product formation in the 
premixed state but no significant change in product formation for the trapped state. This proves 
that the trapped state is in fact trapped, as the labelled substrate cannot dissociate and bind the 
unlabelled competitor substrate, as a result the original substrate is processed. This study 
demonstrates that hFEN1 must first thread a flap before it can process the substrate 
biochemically, however, whether this could be visualised by structural studies was needed to 
definitively prove this [101]. 
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A crystal structure of hFEN1 threading the 5'-flap of a double flapped substrate through 
the helical gateway of the enzyme has been obtained more recently [99] (figure 4.4). The 
structure shows that hFEN1 is capable of threading its substrates; together with the threading 
and blocking experiments this proves that hFEN1 must thread its flapped substrates before 
catalysis. Whether hEXO1 must also thread its substrates in the same manner is an interesting 
question. The nucleolytic cores of the two enzymes were shown to be conserved in section 
1.4. However, given the dramatic difference in the endonucleolytic rates between FEN1 and 
EXO1 it is unclear whether this mechanism is conserved. Based on previous crystal structures 
it was not thought possible for hEXO1 to accommodate a flapped structure through its helical 
gateway [89] (figure 4.4F). Therefore, studies into the threading capability of hEXO1 were 
performed.  
Figure 4.4: Crystal structure of hFEN1 with a threaded substrate and hEXO1 for 
comparison. Schematic of the double flapped construct used to crystallise FEN1 (A) and 
EXO1 (D), with the colours corresponding to the strands in the crystal. B. Crystal structure 
of hFEN1 (5UM9.pdb) with the substrate in complex with the enzyme, showing the 5' flap 
threaded below the arch and the 3' flap positioned into the binding pocket. C. The back of the 
archway with the 5' flap threaded through the back of the enzyme without clashes or steric 
hindrance. E. Crystal structure of hEXO1 (3QEB.pdb) with the substrate in complex with the 
 73 
 
enzyme. F. The back of the archway of hEXO1 shows a hole that may be too small to 
accommodate a flap through the helical archway.  
The streptavidin trapping experiment briefly outlined before was utilised to study 
whether hEXO1 is capable of threading a substrate, and if yes, whether this step is a necessity 
or a hindrance. There are three states for this experiment; trapped, blocked and premixed 
(streptavidin-free control). For the trapping and premixed experiments, the substrate was 
mixed with enzyme and incubated for 2 minutes at room temperature in a buffer containing 
calcium ions. Calcium ions mimic the catalytic metal ions present in vivo (usually magnesium 
ions) but cannot themselves support catalysis. Depending on the experiment, buffer (for the 
premixed state) or streptavidin (for the trapped state) was added and a further 5 minute 
incubation was performed. Alternatively for the blocked state the substrate is first conjugated 
with streptavidin and incubated for 5 minutes prior to the addition of enzyme and a second 
incubation of 2 minutes at room temperature. Once pre-incubation had been performed 
samples were heated to 37⁰C and initiated with the addition of excess magnesium ions 
followed by quenching at appropriate time points. The reaction scheme of the three states is 
shown below in figure 4.5A. 
Experiments were performed with 10 nM of the PY3 (5' FAM labelled biotinylated 
unimolecular pseudo-Y – see section 2.3) and mixed with 4 μM enzyme during the pre-
incubation period, conditions where it is expected that all substrate will be bound by the 
enzyme. Magnesium ions were added to initiate reaction. The final concentrations after the 
addition of the magnesium buffer was 5 nM substrate and 2 μM enzyme. Samples were taken 
at appropriate time points based on the state being examined, for example the premixed state 
was on a primarily ms timescale as experiments were performed using a quenched flow 
apparatus, whereas the blocked state experiments were manually run until 30 hours. Samples 
were analysed to dHPLC as described in sections 2.4.1 and 2.5.2 with processing via equation 
2.1). The data were fit to either a single or double exponential equation (equation 2.2 and 2.3) 
and plotted in figure 4.5C-D with the exact rates listed. 
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Figure 4.5: The expected trapping scheme and data. A. The premixed (streptavidin-free), 
trapped and blocked states outlined based on the supplementation order. The streptavidin, SA, 
is highlighted in red, and the magnesium buffer is indicated by Mg2+ in blue. This is the 
expected mechanism for trapping and blocking. The ESSA complex represents the trapped 
state and ESAS complex is the blocked state. B. The PY3 construct used for the streptavidin 
threading experiments with hEXO1 (see section 2.3). C. The plot of the threading data, with 
premixed (orange), trapped (blue) and blocked (red), data fit to single or double exponential 
fits (equations 2.1 and 2.2). D. The rates and amplitudes of the fits; the trapped fit is biphasic, 
hence the two separate rates. 
 Upon addition of magnesium, the premixed (streptavidin-free) complex decayed 
relatively quickly with a reaction rate of 0.43 s-1. The data for the blocked state, where 
streptavidin would prevent threading, are slow as expected, with a biologically irrelevant rate 
of 0.0018 s-1. However, the trapped data produced an unexpected result. Roughly 20% of the 
product formed with a fast rate which is around 5-fold faster than for the premixed rate. 
Whereas, the other 80% of product formation was a much slower rate which resembled the 
blocked data (a 2-fold difference). The trapped fit illustrates that around 20% of the substrate 
is successfully threaded and the other 80% is effectively blocked, hence the slow second phase.  
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 To determine whether a lack of saturation of the substrate with enzyme was the cause 
of this fast phase, various concentrations of enzyme were tested in the trapped state (figure 
4.6A). However, the concentrations tested showed no significant difference in proportion of 
fast decaying species with increasing enzyme concentration, suggesting that the substrate is 
saturated by the enzyme in all cases. This suggests an alternative threading mechanism, with 
an on-enzyme equilibrium, whereby the substrate can be bound to the enzyme but not 
threaded. The new mechanism explains the trapped state; it may also be significant in the 
premixed state, as these data fit a two phase exponential (figure 4.6C). A control to determine 
whether the streptavidin concentration of 5 equivalents is enough to proficiently trap the 
substrate was performed using 15 equivalents (figure 4.6D). 
 A biphasic fit of the premixed data in figure 4.5 fits the plotted data points with greater 
accuracy. This double exponential decay could be due to the threading equilibrium 
hypothesised from the saturation experiment. If the enzyme must first bind and then thread a 
substrate, this could account for the biphasic nature of the premixed and trapped states. In the 
premixed state more substrate would be continuously threaded as the reaction is taking place. 
However, upon addition of the streptavidin the substrate can become blocked before it is 
rebound and threaded, hence the small amount of trapped substrate in the experiment. All these 
experiments suggest that hEXO1 must first thread a flapped substrate to cleave it on a 
biologically relevant timescale.   
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 Figure 4.6: Saturation and streptavidin control tests. A. Substrate saturation test with 
increasing enzyme concentrations where 0.5, 1, 2 & 4 μM correspond to the red, blue, yellow 
and magenta lines respectively (these are the final enzyme concentrations after initiation). No 
significant difference in the trapped state is observed by increasing the enzyme concentrations. 
B. The modified reaction scheme for the premixed and trapped states, where EXO1 must first 
thread the flap by an on enzyme equilibrium. This equilibrium is between the unthreaded 
(UTh) and threaded (Th) state. In the trapped state this leads to the substrate being blocked if 
the flap is not threaded. C. The premixed data fit to a double exponential equation, which may 
be more representative of this on-enzyme equilibrium, as more substrate becomes correctly 
positioned over time. D. A test with streptavidin to determine whether increasing the 
streptavidin concentration can increase the amount of substrate trapped. The standard 
concentration used, 5 equivalents, in blue and 15 equivalents in magenta show no difference.  
A series of competition experiments were performed to complement the premixed and 
trapped data. Supplementation with a large excess of unlabelled 3' overhang competitor 
(OVH3) after pre-incubation with enzyme and buffer (premixed) or streptavidin (trapped) was 
followed by a further 10 minute incubation. After the addition of magnesium ions, the reaction 
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was sampled five times at points corresponding to the fast phase of trapped and pre-mixed 
states using quenched flow apparatus. The experiment reveals whether the competitor can 
outcompete the substrate; the non-labelled competitor substrate was 1000-fold more 
concentrated than the labelled biotinylated substrate. In the premixed state, the substrate was 
expected to be outcompeted. Whereas a substrate that has been successfully trapped on the 
enzyme cannot dissociate, preventing the competitor from binding (figure 4.7A). Therefore, 
the rate of product formation of the premixed state should be drastically reduced, whereas the 
trapped experiment would remain unchanged in the fast phase.  
 The competition data agreed with the conclusions of the earlier streptavidin 
experiments. The streptavidin-free control product formation rate is reduced by the addition 
of the competitor (figure 4.7B). Whereas, the trapped state is unaffected by the addition of the 
competitor, which demonstrated that the substrate was indeed trapped on the enzyme, and 
could not dissociate (figure 4.7C). No competition experiment was performed with the 
blocked state as the rate is already not biologically relevant, and the competitor would just 
slow this rate further. This effect may also occur with the trapped slow phase, but time points 
taken were specifically tailored for the fast phase of the experiment. Therefore, the fast 
decaying substrate portion is being threaded through the enzyme.  
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Figure 4.7: Threading competition experiments. A. A cartoon of the predicted competitor 
scheme. The addition of the competitor is expected to fill the enzymes active sites before 
catalysis initiation with the addition of Mg2+, unless the substrate is successfully trapped. For 
the premixed (B) and trapped (C) experiments, 5 time points were selected over the course of 
the trapped fast phase (41, 141, 441, 1641 & 6441 ms). The premixed data are represented in 
red, where the lighter pink colour represents the competition experiment, and the red is the 
competitor-free control. The trapped data is depicted in blue, where the lighter shade is the 
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competitor data, and the darker shade is the competitor free-control. The premixed state has 
reduced product formation in the presence of the competitor, whereas the trapped phase 
remains the same over the fast phase.  
 All the data presented in this section suggest that hEXO1 does indeed thread flapped 
substrates in a mechanism analogous to hFEN1, but with a lower efficiency. Another recent 
study using time-lapsed crystallography successfully crystallised stepwise snapshots of the 
enzyme in complex with a flapped substrate [100]. The enzyme was crystallised with a 
pseudo-Y construct which was threaded below the helical arch. It should be noted that these 
crystal snapshots were not successful threaded structures the majority of the time, 
representative of the on-enzyme threading equilibrium. The DNA construct used in both the 
threaded and cleaved crystal structures are visualised in figure 4.8. 
Figure 4.8: EXO1 Threading crystal structures. Time-resolved crystal snapshots of hEXO1 
in the presence of flapped substrates show hEXO1 threading its substrate, like hFEN1 in figure 
4.4. A. The construct used to crystallise the threaded state is a small pseudo-Y construct. B. 
The threaded crystal from the front shows that the DNA substrate is accommodated below the 
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helical cap. C. The back of the enzyme lacks the steric clashes hypothesised to block a flapped 
substrate. D. A crystal showing the threaded state after phosphodiester hydrolysis, which is 
highlighted on the right. For all crystal representations, the helical gateway is highlighted in 
red and the hydrophobic wedge in blue. The crystals represented in B-C. 5V0E.pdb and D. 
5V0D.pdb.  
Therefore, both biochemical and structural studies show that hEXO1 is not only 
capable of threading flapped substrates, but must do so to process these DNA constructs. This 
is comparable to the mechanism by which hFEN1 processes flapped substrates. However, the 
reduced specificity of hEXO1 threading its substrate may account for the lower rate observed 
with a flapped substrate compared to its exonucleolytic substrates. It is unclear whether 
differences in the active site reduce the accommodation of a flap, or if this is due to the 
exonucleolytic processive nature of hEXO1. This will be further examined in the next section. 
4.3 The importance of conserved basic residues in +1 phosphate interaction in hFEN1 
As discussed previously, both hFEN1 and hEXO1 must first thread flapped structures to 
process them on a biologically relevant time scale. The next area of research was aimed at 
studying how the enzyme interacts with the +1 phosphate group and its importance in active 
site positioning of the scissile phosphate.  A simple diagram of the DNA is shown below in 
figure 4.9 which highlights the +1 phosphate and sugar, with the cut site represented by a blue 
dotted line. 
Residues of possible importance for +1 phosphate interaction were selected by their 
crystal contacts with the DNA bound to hFEN1 (3Q8K.pdb). The following work focused on 
hFEN1 mutants of various basic residues to alanine as single or double mutants in an attempt 
to prevent phosphate interactions. As phosphates are negatively charged, the positively 
charged basic residues form a complementary electrostatic environment surrounding them.  
The basic residues were also selected due to good sequence conservation (figure 4.10) across 
species and they are close to various phosphate oxygens. 
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Figure 4.9: A simple representation of the DNA. A double-stranded DNA duplex with ssDNA 
5' flap. Simple nucleotide representations with four nucleobases (orange, purple, blue and 
green), deoxyribose (yellow pentagon) and phosphate molecules (magenta circles). The cut 
site is one nucleotide into the duplex represented by the dotted blue line. The +1 and -1 
nucleotides are highlighted, but the +1 phosphate is the main research topic for this section.  
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Figure 4.10: Selection of residues for +1 phosphate experiments. A. A sequence alignment 
of FEN1 homologs from 15 species aligned using ClustalX2. The region examined 
corresponds to the helical arch and cap. The better conserved basic residues are shown below 
the alignment in red; R100 and K93 were not mutated in this study. Crystal structure 
representations were generated using the D86N mutant crystal (5UM9.pdb). B. A side view 
of the archway with the DNA flap threaded through; K132 and R104 are shown with their 
respective distances to phosphate oxygens. K132 is interacting with the +2 phosphate and the 
R104 residue with the +1 phosphate. R103 is also shown but no visible electrostatic 
interactions are observed. Whereas R129 is proposed to interact with the DNA template strand 
and is within electrostatic range. C. A back view of the threaded flap through the archway, 
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with Y40 stacking on a nucleobase. K132 and R104 are illustrated again, with R100 and K93 
also visible, the latter residues are well known to be essential active site residues. A 
magnesium ion is represented by an orange sphere.  
Of the residues illustrated in figure 4.10, four were selected and tested to determine 
their importance in +1 phosphate interaction. The residues are R103, R104, K132 and R129. 
The first three were selected for their possible direct interactions with the +1 phosphate. The 
last residue is expected to be important in binding to the complementary DNA strand opposed 
to the reacting strand. Alanine single and double mutants were designed to remove the positive 
charge associated with the residues. Also two glutamate double mutants and a quadruple 
mutant were also generated to completely reverse the positive charge. The resulting hFEN1 
mutants will be referred to as R103A, R104A, R129A, K132A, R103A-R129A, R104A-
K132A, R103E-R129E, R104E-K132E and quad-E (R103E-R104E-R129E-K132E).  
The hFEN1 mutants were tested with DF1, which contains a five nucleotide 5'-flap 
and a single nucleotide 3'-flap, by another member of my research group (data is published in 
[REF]), and test the effect of the mutations on the endonuclease activity of hFEN1. In this 
work, wild-type FEN1 and mutant variants were tested with a single-flapped (SF) substrates 
which are suitable for exonuclease cleavage by FEN1. To determine whether mutants directly 
interact with the +1 phosphate at the 5' end (highlighted in figure 4.11), SF substrates with a 
phosphate (SF1) and hydroxyl (SF2) at the 5' position of the reacting strand were tested. The 
data for hFEN1 with the 5' modified SF constructs are shown in figure 4.12. The key difference 
between DF1 and SF1 is that DF1 contains a phosphodiester bond as opposed to a phosphate 
group in SF1, which presents a difference in charge. However, the difference between all the 
mutants and with wild-type is approximately 10-fold in all cases, suggesting that the difference 
in charge is not important for hFEN1 activity. The DF1 data is available alongside the SF1 
and SF2 data on page 163. 
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Figure 4.11: Single 3' flapped constructs. Modifications at the 5' of the SF substrates with 
either a phosphate (A) or hydroxyl (B). Phosphates are coloured purple in the substrate 
schematics, and the hydroxyl is represented with an orange circle. The +1 and -1 nucleotides 
are highlighted in green. The reacting strands are cyan and the template strands are coloured 
in brown.  
Experiments were performed with 50 nM substrate concentrations of either the 3' SF (5' 
phosphate) or 3' HSF (5' hydroxyl) and variable concentrations of enzyme depending on the 
particular mutant used, to produce ~10-20% cleavage over variable time scales. Due to the 
nature of FEN1 as an exonuclease, single nucleotide products were removed and capillary 
electrophoresis was required to separate the 18-nucleotide substrate from the 17-nucleotide 
product. Electropherograms were manually integrated and converted into normalised rates. 
The data for wild type FEN1 and its alanine and glutamate variants are plotted in grouped bar 
charts in figure 4.12.  
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Figure 4.12: FEN1 mutants with +1 modifications. A. Electropherograms of hFEN1 with a 
5'-phosphate or -hydroxyl at the +1 position of single 3'-flap construct (see section 2.3) (SF1 
and SF2 respectively) these peaks are integrated and processed as described in equation 2.1. 
Note, retention times shifted over time; this problem was fixed much later. Wild type (WT) 
FEN1 with the alanine (B) or glutamate mutants (C). Rates with SF1 (purple) or SF2) (orange) 
displaying differences depending on the mutant. Experiments for R103E-R129E and R104E-
K132E mutants with the 5'-hydroxyl substrate were too slow to be accurately measured as 
multiple turnover experiments and are therefore represented with < and ≤ symbols.  
 The data show that each mutant had differing levels of impairment with each 
modification. For the +1 phosphate experiments; R103A and K132A show small decreases in 
rate of 5- and 8-fold compared to wildtype FEN1. The impact of the R104A and R129A 
mutations are greater with 25- and 20-fold respective decreases in reaction rate. Double 
alanine mutants show an additive decrease of their two encompassed mutations with R103A-
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R129A and R104A-K132A displaying a 50- and 140-fold decrease respectively. The double 
glutamate mutations exhibit larger decreases in activity compared to their alanine variants, 
which can be associated with a repulsion effect of the residue charges. The rate decreases of 
R103E-R129E and R104E-K132E were 2700- and 7800-fold respectively, presenting a 
dramatic decrease opposed to the alanine mutants. The QuadE mutant showed an even greater 
decrease in rate, with a 15000-fold decrease in reaction rate. 
 The 5'-hydroxyl data revealed some differences in the impact of the mutants. The 
R103A and R129A mutants show larger (8- and 35-fold) decreases in reaction rate compared 
to wild-type, R103A-R129A exhibits an additive effect of the single mutations with a decrease 
of 140-fold. However, R104A and K132A show minor reductions of around 2- and 1.5-fold 
compared to wild-type. Removing R104 and K132 in combination with the +1 phosphate 
shows a similar decrease in rate compared to wild-type with the 5'-hydroxyl. This suggests 
that these residues directly interact with the 5'-phosphate, as they show no effect compared to 
wild-type in its absence. The double alanine mutant R104A-K132A also displays a similar 
decrease in rate, with a small 4-fold decrease. On the other hand, R103E-R129E, R104E-
K132E and the QuadE mutants were too slow to record on a reliable timescale with the poorer 
substrate.  
 The single mutation rate decreases are suggested to be representative of electrostatic 
guidance interactions; which is an apt explanation for the removal of positive charges [99]. 
Replacing basic residues with glutamates provides a larger decrease in reaction rate, probably 
due to a complete reversal of the residue’s charge, repulsing the 5'-phosphate. Interestingly, 
no significant change in the KD of these mutants (data collected by collaborators and not 
shown) was observed compared to the reduction in reaction rate, suggesting that the loss of 
activity is not due to a reduced ability to bind the substrates [99]. The QuadE mutant has a rate 
comparable to the blocked state for hFEN1 with biotinylated substrates preincubated with 
streptavidin [101]. These data suggest that these mutations disrupt the threading process, and 
are potentially responsible for steering the phosphates into the correct position for cleavage. 
This is especially so for R104 and K132, which our functional data suggests directly interact 
with the +1 phosphate. Streptavidin trapping and blocking studies with these mutants may 
provide interesting insights into the characteristics of each mutant.  
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 These data can be extrapolated slightly to examine the effects of these residues within 
the superfamily. A shortened sequence alignment of the region examined in figure 4.10 of the 
various superfamily members shows conservation of the residues examined. In particular, 
R103 and R104 are consistently conserved through human members. R129 is conserved in 
hEXO1 but this region is not present in hGEN1 and hXPG; this may be due to a lack of the 
helical cap in these enzymes. K132 is not conserved in any of the other family members, 
although it is heavily conserved in FEN1 homologs. Interestingly K132 is important for direct 
+1 phosphate interaction and its absence in hEXO1 may be responsible for the lack of 
precision of flapped substrates. This alignment is shown in figure 4.13 with other key residues 
highlighted in the region. 
The most highly conserved residues in the region, K93 and R100 in FEN1 or K85 and 
R92 in EXO1, have been characterised previously for both proteins and mutations produce a 
large decrease in activity [16, 89]. R100 and R92 mutations in these enzymes are effectively 
catalytically-inert on a biological time-scale. The R92 residue in hEXO1 shows electrostatic 
interaction with the scissile phosphate (figure 4.13B), and R96 shows similar interactions with 
the +1 phosphate as R104 in FEN1 (figure 4.13C). R121, the EXO1 R129 homolog has some 
electrostatic interaction with a nucleobase in the template strand (figure 4.13B), before 
interacting directly with a phosphate in the template strand at the junction, which may be an 
indicator of threading before catalysis occurs.  
Examination of DNA changes between the two structures shows that the template 
strand unwinds and the flapped region moves closer to the metal ions (figure 4.13F-G). The 
Y40 homolog in hEXO1, H36, appears to guide the nucleotides into place by stacking with 
the nucleobase. The second stacking residue, Y32, may have similar interactions before the 
flap is in position, and may account for the change in DNA conformation. The key difference 
between the cleaved and uncleaved states is that the important residues studied in hFEN1 are 
all positioned for catalysis in the cleaved state. The crystal structures examined are snapshots 
of substrate equilibration before cleavage and demonstrate that the residues first reposition the 
DNA before catalysis can occur.  
A simple test with hEXO1 and a 5'-hydroxyl nicked duplex (ND3) gave an interesting 
result compared to that observed with hFEN1 (figure 4.14). Where hFEN1 and its mutants 
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perform a single exonucleolytic cut one nucleotide into the duplex, hEXO1 either removes 
one large tract of DNA or the hydroxyl end group drives the protein’s processive nature 
(described in section 3.4), as the first product of a single nucleotide excision has a greater 
affinity for hEXO1 in this case. However, this has yet to be confirmed, but future work in this 
area for hEXO1 could provide interesting insight. 
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Figure 4.13: Conservation of +1 phosphate residues and examination of hEXO1 crystals. 
A. Sequence alignment of FEN superfamily members, highlighting key residues within the 
helical arch and cap region. The hEXO1 homologs of the mutants used in hFEN1 are 
highlighted. Crystal structure representations of hEXO1 in a threaded state where the DNA is 
either threaded (5V0E; B-C) or cleaved (5V0D; D-E). A side (B) and back (C) view of the 
uncleaved threaded structure displaying the interactions and distances of the particular 
residues shown to be conserved. In this crystal the DNA is not in the correct conformation, 
with the scissile phosphate being 12 angstroms from the cations. Some interactions are present 
with the various basic residues. A side (D) and back (E) view of the cleaved crystal structure 
shows closer distances between the key residues and their respective targets, suggesting that 
once the flap is threaded and in the correct position, catalysis can occur. The DNA of the 
uncleaved (F) and cleaved (G) crystals with the differences highlighted for substrate steering, 
which back up the concept of a correct position for catalysis.  
Figure 4.14: EXO1 cleavage patterns. Electropherograms of hEXO1 with nicked duplexes 
with a 5' phosphate (A) and 5' hydroxyl (B), which are both labelled with a 3' fluorescein. The 
substrate peaks are both 18 nucleotides. Assays with the 5' phosphate show a ladder forming, 
where each duplex product can be processed as readily as the initial substrate. However, 
assays with the 5' hydroxyl nicked duplex showed formation of a single smaller product, where 
it is unclear whether the enzyme is cutting as an endonuclease or by acting processively. 
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 4.4 Summary of endonuclease studies 
The endonuclease capability of hEXO1-352 is much slower compared to hFEN1 (90-fold), 
whereas the exonuclease ability of the two enzymes is relatively similar. However, this may 
be due to the processive nature of hEXO1, and the fact that the simple multiple turnover 
experiments performed do not truly measure this ability. Rather importantly, a 10-fold increase 
in rate is observed when only one 5' end is available for catalysis, which would suggest that 
more than one activity is occurring in bimolecular substrates, resulting from additional binding 
modes to the substrate.  
Human EXO1 must first thread a flapped substrate through its helical archway before 
it can perform hydrolysis. However, compared to hFEN1 it is not capable of completely 
trapping the flapped substrate, with only ~20% of the substrate being processed on a 
biologically relevant timescale in a “trapping experiment”. The remainder of the substrate is 
treated around 2300-fold slower than the fast phase, which is comparable to the blocked state 
in which the substrate is unable to thread. Saturation experiments showed that the substrate 
was saturated onto the enzyme, and suggests threading is an on-enzyme effect that can be 
expressed by an equilibrium. These findings complement recent crystal structures of hEXO1 
in a threaded state. These data and the crystallographic evidence demonstrate that hEXO1 
threads flapped substrates to position the flap for catalysis, consistent with claims that hEXO1 
acts as a back-up for hFEN1 in vivo.  
Similar crystal structures were recently assigned for hFEN1 in a threaded state, and 
from these snapshots key residues were selected to test whether they are important in steering 
the phosphates into place. These residues show varying differences in rate when used to 
process a single flap substrate with either a phosphate or hydroxyl at the +1 position. From 
these studies it became apparent that R104 and K132 directly interact with the +1 phosphate, 
whereas R103 and R129 must have other roles in catalysis or interaction with other 
phosphates. These residues are conserved in hEXO1 (except for K132), and may have similar 
roles in stabilising the hEXO1 threaded state.  
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Chapter 5: The Role of Substrate Dynamics in Catalysis 
5.1 Enzyme-induced conformational change 
Previously, a reaction mechanism scheme (see figure 3.5) was used to explain the general 
scheme expected for FEN family members. Kinetic studies were used to examine various 
stages in the cycle, and I identified that product release is rate limiting at high substrate 
concentrations in hEXO1 (chapter 3). Analysis in the presence of calcium ions, which are 
known to bind in a similar place to catalytic magnesium ion but do not permit reaction, allowed 
for examination of the expected conformational change step highlighted in figure 5.1 for 
hFEN1. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Reaction scheme revisited. Reaction scheme highlighting the conformational 
change step in the presence of Ca2+, which is known to inhibit the chemistry of the FEN 
superfamily. 
The conformational change of the enzyme substrate complex for hFEN1 was first 
attributed to double nucleotide unpairing (DNU) [118], where the +1 and -1 nucleotides are 
unpaired for placement of the scissile phosphate between the divalent metals (figure 5.2A). 
This phenomenon has been examined by exciton-coupled circular dichroism (ECCD) using 
tandem 2-aminopurine nucleotides in either the +1, -1 or -1, -2 positions. Once the enzyme 
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binds the substrate a change in the CD signal is assigned to a break in the nucleotide stacking 
at the +1, -1 positions attributed to local unpairing of the DNA. An example of this change in 
signal is shown in figure 5.2B, where a comparison of the signal in the presence and absence 
of enzyme shows a drop in intensity.  
Figure 5.2: Double nucleotide unpairing in hFEN1. A. A cartoon representation of DNU, 
where the +1 and -1 nucleotides are unstacked and positioned between the metal ions. B. An 
ECCD trace of hFEN1 with a double flapped substrate with tandem 2-aminopurines in the 
+1, -1 positions. The red trace represents the substrate alone in buffer containing Ca2+, and 
the blue trace is once enzyme is added; a drop in signal is observed. The Y-axis units is the 
left circularly polarised absorbance subtracted by the right circularly polarised absorbance 
divided by the concentration of 2-AP molecules.   
 The DNU model has been a point of dispute in the study of hFEN1, and recently 
crystallographic evidence with threaded flapped substrates does not show the DNA to be in 
this state. However, in its place the crystal exhibits a distortion in the structure of the DNA 
which could account for the change in CD signal in figure 5.2B. Modelling with perfect B-
form DNA (generated by web3DNA [119]) with the same sequence used for the flapped 
substrate in the crystal structure, the DNA distortion can be observed. In figure 5.3 the 
threaded crystal structure of hFEN1 [99] is examined in detail.  
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 Figure 5.3: Distortion of the DNA substrate with hFEN1. The double flapped (DF) substrate 
overlaid with a perfect B-form helix (BF) from the front (A) and above (B). The DF is coloured 
with a cyan reacting strand, brown template strand and purple 3' flap strand. Whereas, the 
BF DNA is coloured with a green reacting strand and purple template strand. The metals are 
shown to give spatial awareness of the structure. It is clear that distortion is present in all 
regions of the substrate and not just the 5' flap. C. The DF substrate highlighting the -1, +1, 
+2 and +3 nucleotides, displays that the nucleotides are not unstacked from the duplex, 
discounting DNU. D. The BF DNA showing the clear level of distortion needed to reach the 
position of the -1, +1, +2 and +3 nucleotides in the DF substrate. E-F. FEN1 in the presence 
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of the DF (E) and BF (F); the distortion is required for the flap to be correctly positioned 
through the enzyme. 
 To determine whether a similar distortion is required for cleavage by hEXO1, ECCD 
experiments were performed. Spectra were taken of 10 μM substrate (e.g. ND+1-1, OVH+1-1, 
etc) in buffer (CDRB), which contains Ca2+. If samples were in the presence of enzyme, a 12.5 
μM final concentration was used to ensure that the substrate was saturated with enzyme. 
Various constructs were tested with hEXO1, due to its lack of specificity, and a selection of 
the CD spectra are shown in figure 5.4.  
Figure 5.4: ECCD spectra of hEXO1 with tandem 2-aminopurines in the +1, -1 position. 
Spectra of hEXO1 with (A) ND+1-1, (B) OVH+1-1, (C) PY+1-1 and (D) SF+1-1 (see section 2.3). 
The red trace represents the substrate alone and the blue trace is in the presence of enzyme. 
Spectra were taken stepwise over 300-480 nm, but only 300-360 nm is displayed with the 
remainder being used to normalise the traces.  
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 The spectra for hEXO1 in figure 5.4 do not follow the pattern observed for hFEN1 in 
figure 5.2B, with no significant change in CD signal between the ES and S-alone samples. A 
larger range of substrates were tested; a nicked duplex, 3' overhang, pseudo-Y, single flap and 
unimolecular 3' overhang, with tandem 2-aminopurines (2-AP) in both the +1, -1 or -1, -2 
positions (see section 2.3). Spectra were taken in the presence of 10 mM Ca2+ before another 
trace was taken after the supplementation of excess EDTA. The spectra were baseline-
corrected, converted to molar ellipticity, gently smoothed and normalised against the spectra 
taken in the 380-480 nm region. The full data is shown in figure 5.5, where the CD value at 
326 nm (the maxima of tandem 2-AP) was averaged with three repeats. 
Figure 5.5: ECCD data for hEXO1 taken at 326 nm. EXO1 substrates tested in the +1-1 (A) 
and -1-2 (B) positions, with single-stranded DNA (ss), nicked duplex (ND), 3' overhang (OVH) 
and unimolecular 3' overhang (UOVH) substrates. Samples were taken in the presence of Ca2+ 
(red) and excess EDTA (blue). FEN1 substrates tested in the +1-1 (C) and -1-2 (D) positions, 
with single stranded DNA (ss) or single-stranded flapped DNA (ss Flap), a pseudo-Y (PY), 
and a single 3' flapped duplex (SF). Samples are in the presence of 12.5 μM of enzyme when 
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indicated. Bars are colour coded as above, and a hFEN1 control with the single flap is also 
displayed.  
The data in figure 5.5 are evidence that the conformational change observed with hFEN1 is 
not conserved in hEXO1, with little difference in the spectra of hEXO1 with either Ca2+ or 
EDTA (EDTA abolishes the conformational change in hFEN1, due to chelation of the metal 
ions). Therefore, the enzyme-induced substrate conformational change observed in hFEN1 is 
not universal to the family members, and may be important in the precise activity of hFEN1. 
Examination of the +1, -1 and -2 bases from crystal structures for hFEN1 D86N, R100A, 
hEXO1 WT and B-form DNA to determine the level of local nucleotide distortion is displayed 
in figure 5.6. 
The nucleotides examined by ECCD in hFEN1 and hEXO1 are highlighted in figure 5.6, with 
their stacking on one another compared. A distortion in the +1, -1 and -1, -2 nucleotide 
stacking has been observed in hFEN1 previously [99], with the D86N and R100A mutant 
crystal structures showing differing levels of distortion compared to the B-DNA. This 
distortion was expected to be representative of the changes in ECCD signal produced when 
enzyme is added to substrates containing tandem 2-aminopurines. Surprisingly, examination 
of the same nucleotides in hEXO1 (5V08) displays similar local distortion performed by this 
enzyme.  
Currently, no updated hypothesis for the difference in ECCD signal has been 
suggested. However, the DNA backbone in the hEXO1 crystals is more uniform compared to 
the hFEN1 examples. Examination of the threaded crystal structures of hEXO1 with perfect 
B-form DNA demonstrates an interesting stabilisation of the DNA as the ES complex moves 
through catalysis (figure 5.7).  
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Figure 5.6: Nucleotide distortion of FEN1 and EXO1. DNA nucleotides +1, -1 (A-B & E-
F) and -1, -2 (C-D & G-H), where the nucleotides +1, -1 and -2 are red, cyan and orange 
respectively. The nucleotides from hFEN1 variants D86N (A & C), R100A (B & D), and EXO1 
WT (E & G), with B-DNA for comparison (F & H). In each case the reacting strand is on the 
left and the template strand is on the right. The level of local distortion can be examined by 
comparison with the B-DNA. The crystal structures examined were 5UM9 (D86N), 5KSE 
(R100A) and 5V08 (EXO1).  
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Figure 5.7: DNA distortion of the crystal structures of hEXO1. Varying ES states were 
crystallised at differing phases of the catalytic cycle [100]. The helical arch and hydrophobic 
wedge are red and blue respectively. The crystallised DNA is represented with a cyan reacting 
strand and brown template strand. The B-DNA’s match the sequence of the crystallised DNA 
and have a green reacting strand and purple template strand. The crystals for each phase: 
5UZV (A), 5V04 (B), 5V05 (C), 5V08 (D), 5V0A (E) and 5V0D (F). A. Initial DNA binding, 
displays backbone distortion. B. The first rotation of the DNA towards the active site also 
contains minor distortion. C. An intermediate of the second rotation, with similar distortion 
to B. D. Active site positioning shows reduced backbone distortion compared to previous 
states. E. Substrate cleavage of an exonucleolytic substrate is almost in perfect B-form 
conformation. F. Cleavage of a flapped substrate requires DNA distortion, which is consistent 
with FEN1. 
 As demonstrated in figure 5.7, the different stages of hEXO1 interaction with its 
substrate display increasing enzyme-induced stabilisation of the DNA strands in each phase 
towards hydrolysis, as the DNA becomes more B-form throughout the cycle. The various 
stages shown by figure 5.7 from A-E are a continuous cycle starting with substrate binding, 
followed by multiple DNA rotations before active site positioning, and finally hydrolysis. 
These crystals were produced by time resolved crystallography, where samples were frozen at 
different time-points and imaged to examine the results [100]. All the DNA substrates are the 
same except in the case of the flapped substrate cleavage.  
The figure represents a consistent stabilisation of the substrate into a B-form conformation, 
with exonucleolytic cleavage of the DNA appearing to be in a B-form helix. However, panel 
figure 5.7F shows higher distortion when compared to the other states, which is an interesting 
observation as a 5' flapped substrate is present. Therefore, flapped substrates may require 
backbone distortion to be processed. A comparison of the substrate DNA from the threaded 
hFEN1 crystal and hEXO1 threaded crystal is shown in figure 5.8.  
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Figure 5.8: Comparison of hFEN1 substrate distortion with the hEXO1 substrate. A. A close 
up of the DNA used to crystallise hEXO1, which is a cleaved flapped DNA substrate (5V0D), 
aligned to a B-DNA construct. The B-DNA is coloured with a brown template strand and cyan 
reacting strand, whereas the cleaved DNA is coloured with a purple template strand and a 
green reactive strand. The snapshots (i) and (ii) show an examination of the template strands 
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and reactive strands respectively. B. The flapped substrate from hEXO1 aligned with the 
flapped substrate from hFEN1 (5UM9). The EXO1 flapped substrate is coloured as in panel 
A. The FEN1 substrate is coloured brown and cyan for the template and reactive strand 
respectively. Again, the snapshots (i) and (ii) show a comparison of the template and reactive 
strands respectively. The DNA backbone distortion is noticeably larger for hFEN1. 
 The comparisons made in figure 5.8 show that DNA backbone distortion is present in 
hEXO1 when processing a flapped substrate; however, the distortion presented by hFEN1 is 
more severe. Therefore, it can be hypothesised that processing flapped substrates requires 
DNA distortion for accommodation of the 5'-flap through the helical arch. Crystals with 5' 
flapped constructs appear to compress the duplex DNA, possibly to stabilise the flapped strand 
through the active site; this is currently only my conjecture and no physical evidence has been 
provided.  
The idea that hEXO1 stabilises the DNA strands towards B-form upon binding may 
play an important role in realigning the DNA substrate for repeated cleavage by processivity; 
this process would allow for the duplex to slide further into the active site after every 
successive cleavage. The reduced ability for distortion of flapped substrates may simply be 
due to the enzyme’s preference for exonucleolytic cleavage. The more severe backbone 
distortion in hFEN1 may be important for its hydrolytic precision, which successfully cleaves 
at one position the majority of the time, whereas, data presented for hEXO1 show that it 
cleaves multiple positions of an endonucleolytic substrate. All these hypothesises require 
further testing to confirm the nature of the DNA distortion, and no conclusion can be made on 
the exact cause of the ECCD shift that is observable in hFEN1. 
5.2 The limitations of substrate binding techniques with hEXO1 
Attempts at defining the substrate binding phase described by koff/kon in figure 5.1 were 
performed to determine the effect substrate binding has on the cycle as a whole. Two 
techniques were utilised to try and calculate this factor; Förster resonance energy transfer 
(FRET) and fluorescence anisotropy (FA). FRET relies on measuring the energy transfer from 
a donor fluorescent dye to an acceptor fluorescent dye. In an attempt to develop an 
understanding of how the substrate bends when it interacts with the enzyme.  
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 In our FRET assays three differently labelled DNA constructs are used, which are each 
titrated with increasing concentrations of enzyme. In figure 5.9 the three forms of a nicked 
duplex construct for hEXO1 and a double flapped construct for hFEN1 are displayed. The 
three constructs serve different roles in the determination of FRET efficiency. Firstly, an 
unlabelled DNA trimolecular substrate is used which is referred to as NL (non-labelled). 
Secondly, a singly labelled substrate which contains the donor label (in this case fluorescein 
(FAM)) which is referred to as DOL (donor-only labelled). Finally, a doubly labelled substrate 
with both the donor and acceptor dyes (FAM and 5-carboxytetramethylrhodamine (TAMRA) 
respectively), which is known as the DAL (donor-acceptor labelled) substrate. All experiments 
were performed with a buffer containing Ca2+, which renders FEN1 and EXO1 catalytically 
inert, therefore, the substrates are not destroyed by the enzymes. 
 
Figure 5.9: DNA constructs used for FRET. The NDNL, NDDOL and NDDAL substrates (A) 
and the DFNL, DFDOL and DFDAL substrates (B) for hEXO1 and hFEN1 respectively (for 
strands and sequences, see section 2.3). With the reactive strand coloured cyan, the 
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template/acceptor strand coloured brown and the upstream template/donor strand is coloured 
purple. The donor fluorescein dye is represented with the orange star, and the acceptor 5-
carboxytetramethylrhodamine dye by a blue star. C. A schematic illustrating the bending 
associated with enzymatic interaction with the substrate, which is expected to bring the two 
dyes closer together, increasing energy transfer efficiency.  
 Spectra were taken over a range of enzyme concentrations, with the substrate 
concentrations being adjusted to account for the substrate being diluted when enzyme is added. 
The NL acts as a control by removing any change in signal due to the unlabelled substrate 
alone. The DOL and DAL substrates are required to determine the FRET change by the ratio-
A methodology [109]. Experiments with 10 nM substrate are titrated with 0.1-5000 nM 
enzyme. Detection of fluorescence in both the FAM and TAMRA regions was used to 
determine the change in FRET efficiency with increasing enzyme concentrations, which was 
plotted using Kaleidagraph (synergy software). The plotted data was fit to the quadratic 
equation (equation 2.7) with the plots and some of the parameters displayed in figure 5.10.  
Figure 5.10: Plots of FRET data for hEXO1 and hFEN1. Plots of FRET efficiencies for 
hEXO1 (A) and hFEN1 (B) with their respective substrates and increasing enzyme 
concentrations; these efficiencies were determined by use of equations 2.4-2.7 (see section 
2.6). A. EXO1 data with 10 nM [S]0 and between 0.1-5000 nM [E]. B. FEN1 control with 2.5 
nM [S]0 and between 0.1-1000 nM [E]. C. The Kbend, Emin and Emax of the two fits in A and B.  
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The Kbend is the rate of substrate bending when titrated with increasing concentrations 
of enzyme, and represents the enzyme concentration at half the max FRET efficiency. The 
Kbend value determined for hEXO1 is roughly 100-fold higher than the FEN1 control, which 
is a surprising result. Although no published crystallographic evidence demonstrates that 
hEXO1 bends duplex DNA, it is expected to do so as the nicked duplex is its preferred 
substrate. The key difficulty with determining the Kbend of hEXO1 in this case is the lack of a 
plateau in the data, with no end point being observed. In fact, increasing the enzyme 
concentrations lead to a decrease in the FRET efficiency, which could be due to collisional 
quenching, or possibly down to multiple enzyme binding to the same substrate. Therefore, 
further experiments with fluorescence anisotropy were attempted to provide a reliable binding 
constant.  
Fluorescence anisotropy can be used to measure the tumbling of a fluorophore in 
solution. Vertical excitation of the sample before passing the light through an emission 
polariser in either the parallel (vertical) or perpendicular (horizontal) provides intensities that 
can be used to measure the anisotropy (r). Fluorophore labelled (specifically FAM) DNA 
constructs were titrated with increasing concentrations of enzyme. It is expected that as the 
enzyme concentration increases, the tumbling of the fluorophore will decrease as the substrate 
is saturated with enzyme. This can be measured by anisotropy in a fashion that mirrors the 
changes in the FRET experiments. The DNA constructs tested are shown in figure 5.11. 
Figure 5.11: Constructs used in fluorescence anisotropy. The ND2 (A) and OVH2 construct 
(B), which are both 3'-fluorescein labelled (see section 2.3 for strands and sequences). The 
dot represents the unimolecular turn in the DNA sequence. 
 FA experiments were performed with an initial substrate concentration of 10 nM and 
titrated with increasing concentrations of enzyme (between 0.1 and 1000 nM). The total 
intensity (ITOT), the emission of molecules in the same orientation to the polariser (IVV), or the 
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emission perpendicular to the polariser (IVH) and a correction factor against the horizontal 
polarised emissions (G-factor) were determined using the Horiba Jobin Yvon FluoroMax-3 
fluorimeter. These values were used to determine the anisotropy (r) using equation 2.8. The 
anisotropy was plotted against the enzyme concentration and fitted to a variation of the 
quadratic equation (equation 2.8) used with the FRET data (figure 5.12). 
Figure 5.12: Anisotropy data for hEXO1. The data and fits for ND2 (A) and OVH2 (B) 
experiments with the dissociation constant (KD) of the respective fits.  
Experiments were also performed with the DOL nicked duplex in figure 5.9A but the 
data is not significant (the error is double the KD value it predicted, possibly due to a lack of 
end point). The KD determined by the fluorescence anisotropy experiments are all within the 
same order as well as within the same range as the Kbend determined by FRET for the NDDAL 
substrate. It is predicted that these constants are exaggerated in some way. Other research 
groups have reported the KD of hEXO1 to be similar to hFEN1, with a value around 20 nM, 
and a simple explanation may explain the differences [120]. 
Previously, it was suggested that the FRET efficiency may simply be disrupted by 
multiple enzyme molecules binding to the same substrate at different 5' ends. As highlighted 
in figure 5.13A, all the substrates tested have at least two 5' ends that are suitable for EXO1 
binding. Binding of protein to the blunt end would not be predicted to induce a FRET change 
and could potentially be an obstacle to binding to the other 5’-end of the DNA junction that 
would result in enhanced FRET. The study mentioned [120] above uses single-molecule TIRF 
FRET to determine the Kbend of hEXO1 with a substrate with two 5' ends. However, the nature 
of the experiment meant that one of the ends was fixed to a surface before enzyme was added, 
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which could potentially block the enzyme interacting with this end. This process is shown in 
figure 5.13B and suggests a suitable method to overcome this issue. 
Figure 5.13: Overcoming multiple 5' ends. A. The constructs used in both FRET and FA 
experiments have multiple 5' ends, which are suitable substrates of hEXO1. B. The reaction 
mechanism used by [120] to determine the Kbend of hEXO1, where only one 5' end is accessible, 
possibly providing more reliable values. 
 Therefore, future work should be aimed at blocking the 5' ends to ensure precise 
binding at one position and bending of the DNA substrates. This approach may provide lower 
Kbend values that are comparable to hFEN1. Testing these substrates by fluorescence 
anisotropy should also be more reliable.  
5.3 Summary of substrate dynamics 
Exciton-coupled circular dichroism studies with hEXO1 do not provide evidence that an 
enzyme-induced local substrate conformational change that is observed in hFEN1 is shared 
by hEXO1. Further examination of the crystallographic structures of hEXO1 and hFEN1 
modelled with B-DNA display that substrate distortion is required to process flapped 
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substrates. However, when hEXO1 binds to an exonucleolytic substrate, it appears to stabilise 
the DNA strands before catalysis occurs. Förster resonance energy transfer and fluorescence 
anisotropy were utilised to determine the bending and dissociation constants of hEXO1, 
providing relatively high values compared to hFEN1. However, data from another study 
suggests that the binding constant for hEXO1 is more comparable to hFEN1 [120], which may 
be due to blocking interaction with the alternative 5' ends. 
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Chapter 6: Determination of the specificity of a range of N-
hydroxyurea inhibitors for hFEN1 
6.1 Identification of a group of N-hydroxyurea inhibitors for hFEN1 
Human FEN1 is an important enzyme with roles in DNA replication and repair mechanisms, 
generally acting as the key nuclease. Due to its importance for DNA maintenance, it comes as 
no surprise that FEN1 has been observed as both overexpressed and under-expressed in cancer 
cells, allowing for either preservation of cell life or providing greater variation [16, 121-122]. 
Therefore, it would be an effective target for anti-cancer drugs by preventing cancer cells from 
growing. Early work in 2005 [111] was aimed at constructing compounds to inhibit the activity 
of hFEN1, whilst minimising the off-target effect of hXPG inhibition. 
 A high-throughput screen was performed to identify compounds that were capable of 
inhibiting hFEN1 [111]. The most potent compound was named ATH-0013974 and is shown 
in figure 6.1A. This compound has an affinity for hFEN1, with a reasonable IC50 (0.31 μM) 
and the IC50 for XPG is roughly 6-fold higher (1.98 μM). The structure of the compound was 
likened to Flutimide (figure 6.1B), an antiviral drug that targets the influenza endonuclease 
[123]. The proposed binding scheme of the two compounds relies on co-ordination of oxygens 
to the divalent metal ions in the active sites of many nucleases (figure 6.1C). Further 
experiments displayed that removal of the N-hydroxyl eliminated the inhibitory effect of 
ATH-0013974. The study continued to produce a range of N-hydroxyurea compounds based 
on ATH-0013974 to optimise hFEN1 inhibition, whilst reducing inhibition of XPG [123]. 
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Figure 6.1: Compound identified by previous study and its mode of action. The Structures 
of ATH-0013974 (A) and Flutimide (B). C. The predicted mode of action; the compounds co-
ordinate to the divalent metal ions in the active sites of nucleases which rely on a two metal 
configuration. 
 A compound identified in this study (henceforth referred to as compound 1, see figure 
6.2A) demonstrated a 30-fold difference in IC50 for FEN1 against XPG, requiring small 
concentrations to dramatically inhibit hFEN1 (11 and 292 nM for FEN1 and XPG 
respectively). Cell studies with compound 1 showed that it complemented methyl 
methanesulfonate (a DNA alkylating agent) and temozolomide (a DNA methylating agent), 
producing cells that are sensitive to DNA damage [111]. Compound 1 was selected for further 
experiments with hFEN1. To provide an appropriate anticancer treatment by targeting hFEN1, 
it is essential that the drug be specific for the enzyme alone. The compound’s affinity for XPG 
was previously demonstrated to be weak compared to FEN1, but new experiments with 
hEXO1, which is a closer relative to hFEN1, would determine whether the compound is 
suitable. Therefore, studies into whether compound 1, and another newly derived compound 
(compound 2) are hFEN1 specific were undertaken. 
6.2 Determination of the compounds specificity for hFEN1 
The two compounds tested with hFEN1 and hEXO1 are shown below: 
Figure 6.2: The compounds tested. A. N-hydroxy based compounds 1 (athersys) and 2 
(cyclopropylmethyl). B. Crystal structure of compound 1 in the active site of hFEN1 (5FV7), 
consistent with the hypothesised interactions in figure 6.1C. 
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 Work with hFEN1 was previously performed by another student [110, 112] with the 
double flap (DF) construct and the two compounds, demonstrating that they both successfully 
inhibit FEN1 activity. It was shown that the compounds have relatively similar IC50’s (46.4 
and 30.0 nM for compounds 1 and 2 respectively) [112]. To determine whether the compounds 
inhibit hFEN1 as an exonuclease, a single-nucleotide 3'-flapped 5'-FAM labelled substrate 
(SF1) was tested over a range of compound concentrations for comparison. The compounds 
reduced the activity of hFEN1, with the IC50 of compound 1 being essentially equal between 
the single and double flapped substrates. The IC50 of SF1 with compound 2 is roughly 15-fold 
higher, suggesting a weaker interaction. The data for hFEN1 and SF1 with the two compounds 
was analysed via dHPLC as described in section 2.4.3, and is displayed in figure 6.3.  
Figure 6.3: Data for hFEN1 with the 5' SF substrate and compounds 1 & 2. The histogram 
bars are red and blue for compounds 1 and 2 respectively. A. Plot of the initial rates for 150 
nM substrate with increasing concentrations of the inhibitors, the enzyme concentrations 
varied to allow for ~10% cleavage in 10 minutes (see section 2.8). B. The IC50 plot of the 5' 
SF with the two compounds, and the exact IC50 prediction is highlighted in the top right corner.  
 To determine the specificity of the compounds for hFEN1, similar experiments to those 
performed in figure 6.3 were performed with hEXO1 and OVH1 in the presence of the 
compounds. Four concentrations of the compounds were tested (0, 100, 1000 & 10000 nM) at 
a substrate concentration of 150 nM. The data is plotted in figure 6.4 and shows a reduction 
in activity as the concentrations of the inhibitors increased. Approximate IC50 values were 
predicted to be similar to the values determined for hFEN1. Although, more concentrations of 
inhibitor would be required to precisely determine the IC50 values, the inhibitory effect of the 
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compounds on hEXO1 is clear. Moreover, the inhibition of hEXO1 occurs at a similar 
concentration range of compound to the inhibition of hFEN1. 
Figure 6.4: Data for hEXO1 with OVH1 and compounds 1 & 2. The histogram bars are red 
and blue for compounds 1 and 2 respectively. A. Plot of the initial rates with 150 nM OVH1 
with increasing concentrations of the inhibitors, the enzyme concentrations varied to allow 
for ~10% cleavage in 10 minutes (see section 2.8). B. The IC50 plot for the OVH with the two 
compounds, and the rough IC50 predictions are highlighted in the top corner. 
 Therefore, it has been biochemically proven that the compounds are not specific to 
hFEN1 and also inhibit hEXO1 activity with a similar potency. To verify that the compounds 
directly interact with the enzymes and do not act via interaction with the DNA, differential 
scanning fluorimetry (DSF) was performed. DSF can be used to determine the melting 
temperature of the enzyme alone or in the presence of a compound by the use of Sypro Orange 
[124]. This dye can bind to the hydrophobic surface of proteins, but its emission is quenched 
by water. Therefore, as the protein melts the dye can interact with the surface and fluoresce, 
resulting in determination of changes in the melting temperatures by the change in 
fluorescence between the samples. This technique is similar to the in vivo cellular thermal shift 
assay technique (CETSA), which was also employed by our collaborators to demonstrate that 
the compounds interact with hFEN1 in vivo [112]. It is postulated that binding of a compound 
to the enzyme would increase the thermal stability of the enzyme, which would be represented 
by an increase in the melting temperature. Plots of the change in melting temperature (ΔTm) 
against the compound concentrations are shown in figure 6.5. 
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Figure 6.5: Differential scanning fluorimetry of hFEN1 and hEXO1. Changes in melting 
temperature were plotted against the inhibitor concentration. Compounds 1 and 2 are 
represented by red circles and blue squares respectively, with data for hFEN1 (A) and hEXO1 
(B). Experiments in the presence of Mg2+ ions are displayed with unfilled shapes, whereas 
experiments in the presence of EDTA are shown with filled shapes. Compound concentrations 
were used in a range where saturation of the enzyme is expected (little catalytic activity).  
The DSF experiments demonstrate that an interaction is occurring between the 
enzymes and the compounds, measured by an increase in the apparent melting temperature. It 
should be noted that this occurs in a magnesium-dependent manner, as the presence of EDTA 
appears to abolish interaction with the active site directed inhibitor. This observation is 
consistent with the compounds directly interacting and inhibiting catalysis by co-ordination 
with the divalent metal ions in the active site. It can be concluded that these inhibitors are not 
specific to hFEN1, and would probably be too potent for use as a cancer treatment due to their 
off-target effects. 
6.3 The effects of PCNA on FEN1 inhibition 
Our collaborators from Astrazeneca in this study determined an EC50 (effective concentration 
for half maximal response in cells, i.e. death) for compound 1 and compound 3 (IC50 = 16.9 
nM) in SW620 colon cancer cells. Interestingly, compounds 1 and 3 had EC50’s of 5.1 and 6.8 
μM respectively, which are 100- and 400-fold higher for each compound compared to in vitro 
studies. Proliferating cell nuclear antigen (PCNA) forms a trimeric complex known to interact 
with a vast range of proteins involved in DNA replication, repair and metabolism. One such 
protein that PCNA is suggested to interact with is hFEN1, where it supposedly helps to 
stabilise FEN1’s interaction with the DNA (figure 6.6). Therefore, it has been reported that 
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PCNA can stimulate the activity of hFEN1 [125-126]. If PCNA increases the residence time 
of the DNA substrate on hFEN1, so that it is greater than the residence time of the inhibitor 
this could explain the marked differences between cellular EC50’s and in vitro-determined 
IC50’s where PCNA was not present. Thus, to determine whether PCNA could be a factor in 
the in cellular efficacy of the inhibitors, FEN1 inhibition experiments were performed in the 
presence of PCNA. These experiments used an extended version of the double flapped duplex 
substrate (DF2 – see section 2.3), with a 3-fold larger upstream region prior to the 3'-flap (see 
figure 6.6B) which allows for PCNA loading onto the upstream region. Therefore, 
determination of the effect of compound 1 with DF2 was first performed, the data is shown in 
figure 6.6.  
The data in figure 6.6 demonstrates that the IC50 for hFEN1 with the DF2 and 
compound 1 construct is roughly 5-fold higher compared to hFEN1 with DF1. This is within 
a similar biological range and is still suitable for experiments with PCNA. Experiments with 
hFEN1, DF2 and compounds 1 and 3 were performed with increasing concentrations of 
PCNA. In vivo, PCNA requires loading onto the DNA by replication factor C (RFC). 
However, it was suggested for the same process to occur in vitro with excess PCNA without 
RFC [126]. Therefore, samples with a fixed concentration of 10 μM of either compounds 1 or 
3, with increasing concentrations of PCNA (0, 100, 1000 & 10000 nM) to ensure effective 
loading onto the DNA. The data for this experiment, and the structure of compound 3, are 
displayed in figure 6.7. 
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Figure 6.6: PCNA with FEN1 and data of hFEN1 with the DF2 and compound 1. A. FEN1 
and PCNA crystal sturctures (3Q8K and 1UL1) modelled together to give a representation of 
the expected interaction of PCNA and FEN1. B. The DF2 construct used in PCNA 
experiments. C. IC50 plot for hFEN1 with DF2 and compound 1 with the exact IC50 of the 
substrate in the top right corner.  
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Figure 6.7: The effects of PCNA on FEN1 inhibition. A. The structure of compound 3, N-
hydroxy based 4-methoxybenzyl. B. The rate of 150 pM hFEN1 with 150 nM DF2 and 
increasing concentrations of PCNA, with 10 μM of either compound 1 (red) or 3 (purple). 
Increasing PCNA concentrations appeared to reduce activity of hFEN1.  
 The data shows that PCNA does not protect hFEN1 from inhibition with the 
compounds in vitro; in fact PCNA appears to reduce the activity of hFEN1. No inhibitor-free 
PCNA control was performed, but as the PCNA-free sample has a similar rate to hFEN1 with 
DF2 and 10 μM of compound 1 (figure 6.6C – where log[inhibitor] = 4) it is assumed that the 
PCNA is not responsible for the drop in hFEN1 rate. These results contrast with earlier 
literature reports that suggest stimulation of the FEN1 reaction by PCNA. Inhibition by PCNA 
is an interesting observation, but may just be representative of an oversaturation of PCNA to 
the DNA substrate. For example, the binding of PCNA to the reacting duplex arm of the 
substrate rather than the 3’-flap side might be expected to inhibit the FEN1 reaction by 
inhibiting the interaction of protein and DNA. However, these results suggest that hFEN1 
cannot be protected from inhibition by the addition of PCNA. It would be interesting to 
determine whether this is due to inefficient loading of the PCNA to the DNA substrate, but 
that would require future work.  
6.4 Summary of the inhibition experiments 
A range of N-hydroxyurea based inhibitors were previously developed and optimised for their 
ability to inhibit hFEN1 whilst having a minimal off-target effect on hXPG. One of these 
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compounds was selected from this study, which has been crystallised with hFEN1 displaying 
that the compound co-ordinates directly with the divalent metal ions [112]. Studies with this 
compound (compound 1) and another later derived compound (compound 2) showed they had 
similar inhibitory effects on both the exonucleolytic and endonucleolytic activities of hFEN1. 
Further tests with hEXO1 demonstrated that the compounds are not specific to hFEN1, 
reducing the activity of hEXO1 with similar potency.  
Differential scanning fluorimetry was used to confirm that direct interaction is 
necessary between the enzymes and the compounds. These experiments demonstrated that the 
compounds interact with hFEN1 and hEXO1 in a magnesium-dependent manner, consistent 
with the compounds co-ordinating in the active site. Finally, studies to determine the effect of 
PCNA stimulation on hFEN1 inhibition displayed that increasing concentrations of PCNA 
with a fixed inhibitor concentration of either compound 1 or 3 actually reduced the activity of 
hFEN1. Therefore, PCNA interaction does not protect against FEN1 inhibition in vitro.   
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Chapter 7: Conclusions 
7.1 The conclusions of this research 
The work detailed in this thesis is focussed at further understanding the mechanism of the FEN 
superfamily of 5' nucleases, which operate in DNA replication, repair and metabolism. To do 
this, extensive research primarily aimed at studying human exonuclease-1 (hEXO1) and 
making comparisons with what is already known about human flap endonuclease-1 (hFEN1). 
Early experiments determined the substrate specificity of hEXO1 followed by general kinetic 
studies of its exo- and endo-nucleolytic capabilities. Further work into whether there is a 
requirement for threading 5' flapped substrates and if DNA distortion is present, which are 
both precursors of hFEN1 catalysis, were tested in hEXO1. Finally, a group of inhibitors 
known to knock-down the activity of hFEN1 [111] were assayed with hEXO1 to determine if 
they are specific to hFEN1, for possible use in the treatment of cancer.  
 In vivo, hEXO1 is involved in multiple DNA repair mechanisms, including eukaryotic 
mismatch repair and double strand break repair [105]. In each pathway a different substrate is 
processed by hEXO1. Therefore, in chapter 3 the substrate preference of hEXO1 was 
determined, prior to further kinetic studies being undertaken. Three exonucleolytic substrates 
were tested, a blunt duplex, 3' overhang, and nicked duplex, each with either a 5' fluorescein 
(FAM) label or a 3' FAM label (with a 5' phosphate). The results suggested that the nicked 
duplex, which is the major target of mismatch repair, was the preferred substrate for hEXO1, 
consistent with both labelled constructs.  
 Determination of the Michaelis-Menten parameters for hEXO1 with the nicked duplex 
(with differing positions for fluorescent labels) provided kcat’s of approximately 25 min-1 and 
Km’s of 8 and 18 nM (for 5' and 3' FAM labels respectively). Further experiments using 
quenched flow kinetics attained a single turnover kST rate of approximately 260 min
-1, which 
is roughly 10-fold higher than the kcat. As highlighted in figure 3.5, kcat encompasses the rates 
of the conformational change of the enzyme-substrate complex, followed by the chemical rate 
of the catalytic step, and finally the rate of product release. In contrast, the kSTmax is comprised 
of only the conformational change and chemistry step of the reaction mechanism. Therefore, 
as kST was 10-fold faster than the enzymes kcat this implies that product release is a rate-limiting 
step in hEXO1 catalysis at high concentrations of substrate. This may be due to hEXO1 being 
a processive enzyme in vivo [116] (although it only has mild observable processivity in vitro) 
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and as a result the enzyme may hold onto the major duplex product and continue to process it 
as a substrate. Previous studies with hFEN1 observed a comparable Km value, but with a kcat 
roughly 6.5-fold higher than determined for hEXO1. Overall the two enzymes have relatively 
similar kcat/Km values.  
 It has been suggested that hEXO1 can act as a loose back up for hFEN1 in vivo, acting 
in Okazaki fragment maturation [127-129]. Processing the ends of Okazaki fragments requires 
endonucleolytic capability, removing a long flapped structure (as opposed to single 
nucleotides). In chapter 4, the endonuclease capability of hEXO1 was tested by use of pseudo-
Y constructs, equipped with either a 5' or 3' FAM label (as before). The results showed that 
the endonucleolytic activity of hEXO1 is roughly 35-fold slower than exonucleolytic 
processing of the nicked duplex. However, use of a unimolecular substrate, which only has a 
flapped 5' end with elimination of a duplex 5' end, provided a rate much more comparable to 
the nicked duplex (only 4-fold down). Comparing the exonuclease and endonuclease 
capabilities of hEXO1 and hFEN1 suggests that the two enzymes have similar exonuclease 
activity, but hFEN1 has a roughly 70-fold higher endonuclease capability. 
 The mode of 5' flap positioning was an area of controversy in FEN1 research for many 
years, which has been proven biochemically and crystallographically to use a threading 
mechanism, where the 5' flap is threaded through a helical gateway and under the helical cap 
[99, 101]. Similar biochemical experiments to those used to study hFEN1 were performed 
with hEXO1 in chapter 4. These relied on either trapping a biotinylated pseudo-Y construct 
threaded through the helical arch of the enzyme with streptavidin (which forms a high affinity 
interaction with biotin) or blocking the substrate from adopting the threaded state by 
preincubation with streptavidin prior to the addition of the enzyme. The results provide 
interesting insights into the requirement for hEXO1 to thread flapped substrates, which was 
essential for catalysis on a biologically relevant time scale. Attempts to compete away this 
threaded state with an excess of unlabelled exonucleolytic construct were unsuccessful, 
implying that threading does indeed occur. However, when it was attempted to trap the 
substrate on hEXO1, the data were biphasic in nature; only 20% of the substrate reacted 
quickly and was therefore trapped, and the remainder behaved as though it was blocked from 
reaction on a fast timescale. This is postulated to be due to an on-enzyme equilibrium for flap 
threading. This contrasts with hFEN1 where 100% of the substrate adopts a trapped state. 
 123 
 
Another laboratory also published crystal structures of hEXO1 in a threaded state, which backs 
up this biochemical data [100]. Therefore, hEXO1, like hFEN1, must thread flapped substrates 
before catalysis can occur. 
 Building on the requirement for hFEN1 to thread 5' flaps, residues were identified by 
their positioning in the threaded crystal structures [99] based on possible interactions they 
make with the +1 phosphate, which may stabilise the threaded state. Various basic FEN1 
residues were mutated to alanine residues, removing their associated charges before testing 
the effect with a single 3' flapped substrate with either a phosphate or hydroxyl at the 5' end 
of the reacting strand. Both single and double mutant variants were examined and it was 
determined that R104A and K132A have similar lower rates when processing a 5' hydroxyl 
compared with wild type hFEN1, suggesting that they both interact directly with the +1 
phosphate. This effect was additive in the R104A-K132A double mutant, and when the 
residues were mutated to glutamate it was further detrimental. It should be noted that other 
residues tested (R103 and R129) also reduced the activity of hFEN1 with the substrate with a 
5' phosphate, and activity reduction was more severe with the 5' hydroxyl. R104 is conserved 
through the superfamily and may be required for phosphate stabilisation; however, K132 is 
only present in hFEN1. The lack of conservation of K132 in the superfamily suggests its 
importance in maintaining the precision of hFEN1 catalysis one nucleotide into the duplex.  
 Previous studies suggested that human FEN1 induces double nucleotide unpairing on 
its DNA substrates to facilitate positioning of the 5' flap in the active site [16, 118], which is 
expected to cause a change in ECCD signal using substrates containing tandem 2-amino purine 
nucleotides. However, later crystallographic data provided evidence that the DNA is not 
unpaired as expected; instead hFEN1 distorts the DNA to position it in the active site [99]. 
This distortion was expected to be the cause of the changes in ECCD signal. In chapter 5, 
attempts to duplicate this signal change in hEXO1 showed little change, if any, with a range 
of exonuclease and endonuclease substrates with tandem 2-aminopurines. However, 
examination of the local nucleotide stacking in hEXO1 also displayed the nucleobase 
distortion observed in hFEN1 crystals. Further examination of the DNA from various 
published hEXO1 crystal structures displayed small amounts of distortion in the DNA strands 
of exonuclease substrates, appearing similar to B-form DNA. In fact, the later the stage of the 
catalytic cycle that the crystal was in, the more stable the DNA backbone appeared. On the 
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other hand, EXO1 crystals with an endonuclease substrate demonstrate more distortion before 
catalysis, in line with hFEN1 crystals. It is postulated that hEXO1 stabilises the DNA strands 
of exonuclease substrates allowing for consecutive hydrolysis in a processive manner. 
Alternatively, a flapped substrate may require DNA strand distortion to force the flap through 
the helical arch. It remains unclear what the cause of the ECCD signal shifts in hFEN1 is at 
this time. 
 To better understand the conformational change step of catalysis, which is expected in 
FEN superfamily members, substrate dynamic studies were performed in chapter 5. 
Determination of Kbend and KD values for hEXO1 were achieved using Förster resonance 
energy transfer (FRET) and fluorescence anisotropy (FA) respectively. Both techniques 
demonstrated values of approximately 500 nM for Kbend or KD, which suggesting that the 
enzyme binds to and bends its substrates weakly. This was unexpected as rate constants 
determined for hFEN1 are much lower [118]. Another study acquired KD values for hEXO1 
that were much more comparable to hFEN1 by blocking additional 5'-ends from EXO1 
interaction [120]. In chapter 4, it was demonstrated that providing a singular 5' end raised the 
rate of hEXO1 with a pseudo-Y construct by 10-fold. Therefore, it is plausible that hEXO1 is 
interacting with the multiple 5' ends, preventing binding (and bending) of the substrate in the 
expected site, resulting in a much larger value for Kbend and KD. However, further work is 
required to investigate this hypothesis. 
 A range of N-hydroxyurea-based compounds were previously shown to specifically 
inhibit hFEN1 compared to hXPG [111]. Further development of these compounds provided 
two compounds with decent potency for hFEN1, and little effect on hXPG [112]. However, 
EXO1 is more closely related to FEN1 than XPG is; therefore, determination of specificity to 
FEN1 over EXO1 was important. In chapter 6, kinetic experiments with hEXO1 over a range 
of inhibitor concentrations demonstrated a comparable decrease in rate to that of hFEN1 with 
both compounds. Further studies with differential scanning fluorimetry, a technique which 
determines the change in thermal stability of an enzyme by comparison of samples in the 
presence and absence of a compound. Both hFEN1 and hEXO1 showed increases in thermal 
stability with increasing concentrations of both compounds, in a magnesium-dependent 
manner, consistent with the compounds binding the metal ions in the active site. Therefore, 
these inhibitors are not specific to hFEN1. 
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 Experiments using compound 1 and 3 were tested on a human cancer cell line by a 
collaborator. However, these studies displayed roughly 100- and 400-fold higher EC50 than 
the IC50’s determined in vitro [112]. In the literature it has been suggested that proliferating 
cell nuclear antigen (PCNA) is capable of enhancing the activity of hFEN1 in vivo [125-126]. 
In chapter 6, experiments with hFEN1, a double flapped substrate and either compound 1 or 
2 at fixed concentrations were assayed with increasing concentrations of PCNA to determine 
whether it was capable of protecting FEN1 from inhibition.  Intriguingly, this experiment 
demonstrated that hFEN1 is not protected from inhibition in vitro, and also displays a 
reduction in activity with increasing PCNA concentrations, which may be due to 
oversaturation of the DNA substrate. Therefore, interaction with PCNA appears unlikely to be 
the responsible for this higher EC50 value. 
7.2 Future work 
 Future work needed as a result of this project includes developing a better 
understanding of hEXO1-352 as a processive enzyme. Also tests to determine whether 
unimolecular substrates have a faster exonuclease rate compared to their bimolecular 
counterparts. These two results could determine whether the observed Michaelis-Menten 
parameters are representative of the full activity of hEXO1. Secondly, replication of the key 
mutants in hFEN1 used to examine +1 phosphate interactions would be interesting to test with 
hEXO1. Particularly, the R104 equivalent, which is conserved throughout the superfamily, 
may provide useful insight as it directly interacts with the +1 phosphate [16, 99]. However, 
K132 is not conserved in hEXO1. Thirdly, determination of the cause of the CD shift in hFEN1 
which is not observed in hEXO1 would be important (section 5.1). Finally, blocking the 
alternative 5' ends of the FRET and FA substrates may settle whether they are the cause of the 
high KD and Kbend values determined for hEXO1 (section 5.2), or if they are in fact accurate 
results. This is only the beginning of research into hEXO1 and future work will be even more 
insightful than what has been demonstrated in this thesis.  
7.3 Implications of this research on the flap endonuclease superfamily 
 The exo- and endo-nucleolytic rate of hEXO1 and hFEN1 are representative of their 
biological roles, and may not be representative of the FEN superfamily. The superfamily can 
be divided into two subclasses of enzyme; those that process continuous or discontinuous 
substrates. EXO1 and FEN1 hydrolyse discontinuous substrates with bifurcated constructs, 
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therefore, it is unsurprising that both enzymes are capable of threading flapped substrates. 
However, as GEN1 and XPG process continuous DNA substrates, they are not expected to 
have threading capabilities. It would be interesting to examine the effect of the conserved +1 
phosphate residues in hEXO1 and the other members of the superfamily.  
 Equally, studies examining the ECCD signal changes with GEN1 and XPG may be 
more fruitful compared to EXO1 due to their ability to pass the substrate between their helical 
wedged regions. This would be especially interesting with hGEN1, which acts as a dimer in 
vivo. Finally, compound 1 which was assayed with hFEN1 and hEXO1 is known to inhibit 
XPG with a lower affinity [111], which is also expected for compound’s 2 and 3. As these 
compounds co-ordinate to the active site metals of FEN1 and EXO1, it is hypothesised that 
GEN1 will also be inhibited due to its similar catalytic architecture, but testing would be 
required. However, the effect of these compounds may differ due to GEN1 acting as a dimer 
on its substrate. Therefore, further experiments with the compounds and the remaining 
superfamily members may be interesting.  
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Figure A1: The optimised hEXO1-352 sequence used. The codon optimised sequence of 
hEXO1-352 used herein (Seq_1 – obtained from gene art) aligned against the hEXO1 gene 
sequence (Seq_2). The Seq_2 sequence is truncated at 352 codons.  
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Figure A2: Human EXO1-352 plasmid created. The pET21a plasmid with the hEXO1 gene, 
truncated to produce only 352 amino acids (purple). The gene insertion contains a turboTEV 
cleavable 6 histidine tag (green).  
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Figure A3: Human EXO1-352 protein sequence. The protein sequence expected to express 
from the plasmid, with 6-His tag in blue, which is cleavable by TurboTEV (Biochemistry, Ltd) 
using the site highlighted in red. The TEV cleavage site is highlighted, the protein purified 
and used in the experiments is between G2 and Q360.  
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